1	REPORTER'S RECORD
2	VOLUME 1 OF 1 VOLUME TRIAL COURT CAUSE NO. D-1-N-22-7149
3	RUIZ, ET AL,) IN THE DISTRICT COURT Plaintiff,
5	VS. TRAVIS COUNTY, TEXAS
6	TDCJ, ET AL, befendant. 345TH JUDICIAL DISTRICT
7 8	
9	
10	
11	
12	EMERGENCY MOTION FOR TEMPORARY INJUNCTION
13	
14 15	
16	On the 10th day of January, 2023, the following
17	proceedings came on to be heard in the above-entitled and
18	numbered cause before the Honorable Catherine A. Mauzy
19	Judge Presiding, held in Austin, Travis County, Texas
20	REMOTELY VIA VIDEOCONFERENCE:
21	Proceedings reported by machine shorthand.
22	
23	
24	
25	

1	<u>APPEARANCES</u>
2	
3	FOR THE PLAINTIFFS BALENTINE AND RUIZ:
4	MR. ALEX KURSMAN SBOT NO. 19106546
5	AND MS. HAYDEN NELSON-MAJOR
6	AND MS. JENNAE SWIERGULA
7	Federal Community Defender Office in the Eastern District of Pennsylvania
8	601 Walnut St 545 West Philadelphia, PA 19106
9	Phone: (215) 928-0520
10	MR. DANIEL WILSON
11	SBOT NO. 24070859 SUSMAN GODFREY
12	1221 Lamar St., Ste 1000 Houston, Texas 77010
13	
14	FOR THE PLAINTIFF FRATTA:
15	MR. TIVON SCHARDL SBOT NO. 24127495
16	FEDERAL PUBLIC DEFENDER FOR THE WESTERN DISTRICT OF TEXAS, CAPITAL HABEAS UNIT
17	919 Congress Ave, Ste 95- Austin, Texas 78701
18	FOR THE DEFENDANTS:
19	MS. LEAH OLEARY
20	SBOT NO. 24079074 AND
21	MR. ED MARSHALL ASSISTANT ATTORNEY GENERAL
22	PO Box 12548 Austin, Texas 78701
23	Phone: (512) 350-1528
24	
25	

1	
2	FOR THE INTERVENOR ARTHUR BROWN JR.:
3	MR. BENJAMIN WOLFF OFFICE OF CAPITAL AND FORENSIC WRITS
4	MR. PAUL MANSER FEDERAL HABEAS COUNSEL
5	TEDERALE TIMBERIO GOORGEE
6	MR. JAMES RYTTING SBOT 24002883
7	HILDER LAW 819 Lovett Blvd
8	Houston, Texas 77006
9	
10	
11 12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

1	INDEX				
2	VOLUME 1				
3	EMERGENCY MOTION FOR TEMPORARY INJUNCTION				
4	JANUARY 10, 2023				
5	<u>Page Vol.</u>				
6	Announcements 6 1				
7	Opening by Mr. Kursman				
8	Opening by Ms. O'Leary				
9					
10	PLAINTIFF'S WITNESS				
11	<u>Direct</u> <u>Cross</u> <u>Voir Dire</u> <u>Vol.</u>				
12	MICHAELA ALMGREN By Mr. Kuraman 22 71				
13	By Mr. Kursman 22,71 1 By Ms. O'Leary 66 1				
14	INDEX CONTINUED				
15	Closing Argument by Ms. Nelson-Major Page 73 1				
16	Closing Argument by Ms. Nelson-Major 73 1 Closing Argument by Ms. O'Leary 86 1 Closing Argument by Mr. Kursman 93 1				
17	Court Takes Ruling Under				
18	Advisement				
19	Court Reporter's Certificate				
20					
21					
22					
23					
24					
25					

1	EXHIBIT INDEX					
2						
3	<u>PLAINTI</u>	FF'S				
4	NO. DES	CRIPTION	<u>OFFER</u>	<u>ADMIT</u>	<u>VOL.</u>	
5	1 CV		26	26	1	
6	3 USI	Chapter 797	35	35	1	
7	4 USI	Chapter 71	37	37	1	
8	5 US	P Chapter 790	38	38	1	
9	6 Sto	orage Inventory	10	11	1	
10	7 Sto	orage Inventory	10	11	1	
11	8 Em	ail	10	11	1	
12	9 Em	ail	10	11	1	
13	10 La	b Report	10	11	1	
14	11 Ex	ecution Procedure	10	11	1	
15						
16						
17						
18						
19						
20						
21						
22						
23						
24						
25						

1

07:21AM 2

07:23AM 3

10:10AM 4

10:10AM 5

10:10AM 6

10:10AM 7

10:10AM 8

10:10AM 9

10:11AM 10

10:11AM **11**

10:11AM 12

10:11AM 13

10:11AM **14**

10:11AM 15

10:11AM 16

10:11AM 17

10:11AM 18

10:11AM 19

10:11AM 20

10:11AM 21

10:11AM 22

10:11AM 23

10:11AM 24

10:12AM 25

PROCEEDINGS

January 10, 2023

THE COURT: Let me call for hearing Cause No. D-1-GN-22-7149 Wesley Ruiz, John Balentine, Robert Fratta versus Texas Department of Criminal Justice, Et Al.

Your appearances for the record, please.

MR. KURSMAN: Good morning, Your Honor.

Alex Kursman for Petitioners Balentine and Ruiz. This morning Ms. Swiergula filed an order with the Court asking for pro hac vice admission for myself and my colleague, Hayden Nelson-Major. I just want to make sure that order was granted before the hearing begins.

THE COURT: I am told that that has been filed. I'll need to, yeah, take that up and get that signed. We might take a little break after we do appearances since that order -- I'll take appearances and then I'll see if there's any objection. I don't think there should be.

I'm going to ask everyone as you give your appearances or if you go through, because I have so many counsel appearing this morning, if everyone could go through and change their name and include who they represent. It may not all show up and it may not be possible, but we can try.

10:12AM	1	Mr. Kursman and Ms. Swiergula, and who else
10:12AM	2	do I have, please.
10:12AM	3	MS. NELSON-MAJOR: This is Hayden
10:12AM	4	Nelson-Major with the Federal Community Defender Office
10:12AM	5	in the Eastern District of Pennsylvania on behalf of John
10:12AM	6	Balentine and Wesley Ruiz.
10:12AM	7	MR. WILSON: Good morning, Your Honor.
10:12AM	8	Daniel Wilson with Sussman Godfrey as additional counsel
10:12AM	9	for Ruiz and Balentine, and I filed a notice of
10:12AM	10	appearance this morning.
10:12AM	11	THE COURT: Thank you.
10:12AM	12	(Zoom audio distortion)
10:12AM	13	MR. SCHARDL: Good morning, Your Honor.
10:12AM	14	This is Tivon Schardl from the Federal Defender Office
10:12AM	15	here in Austin for Robert Fratta.
10:12AM	16	THE COURT: Thank you.
10:12AM	17	MR. WOLFF: Good morning, Your Honor. My
10:12AM	18	name is Benjamin Wolff. I'm with the Office of Capital
10:13AM	19	and Forensic Writs, and along with Paul Manser, who is
10:13AM	20	federal habeas counsel, we represent Arthur Brown, Jr.
10:13AM	21	We filed a petition intervention yesterday.
10:13AM	22	MS. O'LEARY: Good morning, Your Honor.
10:13AM	23	Leah O'Leary from the Attorney General's Office. I
10:13AM	24	represent TDCJ, Brian Collier, Bobby Lumpkin and Kelly
10:13AM	25	Strong, the Respondents.

10:13AM	1	THE COURT: Thank you.
10:13AM	2	Anyone else? Before I begin, I need to
10:13AM	3	look at those pro hac vice
10:13AM	4	MR. MARSHALL: This is Ed Marshall. I'm
10:13AM	5	also here on behalf of Respondents.
10:13AM	6	THE COURT: Thank you, Mr. Marshall.
10:13AM	7	All right. Before I need to look at
10:13AM	8	those pro hac vice orders and get those filed. Let me
10:13AM	9	just ask, does anyone have any objection to those? I
10:14AM	10	have not had a chance to look at those yet.
10:14AM	11	MS. O'LEARY: No objection, Your Honor. I
10:14AM	12	believe they are filed as unopposed.
10:14AM	13	THE COURT: Okay, great. I'll take a
10:14AM	14	little break. Let me give you some preliminary
10:14AM	15	announcements. I'll take a break and get those signed so
10:14AM	16	that we can proceed. We are holding today's hearing
10:14AM	17	today remotely on the Zoom platform.
10:14AM	18	(Court's COVID instructions.)
10:14AM	19	MR. KURSMAN: We have an expert witness
10:14AM	20	that needs to be through by 1:30 eastern time.
10:14AM	21	THE COURT: That's fine. I'm assuming,
10:16AM	22	Ms. O'Leary, you don't have an objection to that.
10:16AM	23	MS. O'LEARY: Our position is going to be
10:16AM	24	that we don't need to reach the expert at all. We also
10:16AM	25	have some housekeeping matters like objections to

10:16AM 1 exhibits that have been filed.

And we'd like to understand the scope of the hearing. The hearing has only been noticed for Mr. Fratta's amended emergency motion for temporary injunction. So we haven't been noticed to hear the original petition in the case, and we just want to make sure that we understand that correctly.

THE COURT: We'll get to all those housekeeping matters in a minute. Let me take care of those pro hac vice motions and orders. I'm going to take a short break and in the meantime you-all can stand by. Let me get those orders taken care of and then we'll go right into the housekeeping matters, into the evidence, realizing that we have a witness who needs to be done by 12:30 our time. Thank you.

(Whereupon There was a Break in the Proceedings)

THE COURT: I've reviewed the motions for pro hac vice for Mr. Kursman and Ms. Nelson-Major and I have signed those and we'll get those filed. So now let's begin. We can go ahead and begin with any housekeeping matters that we need to take up.

MS. O'LEARY: Yes, Your Honor. We have some objections to the exhibits that were uploaded last night. We can address those now or I'm happy to address them as we go, as Petitioners try to offer them.

10:16AM 2 3 10:16AM 4 10:16AM 5 10:16AM 10:16AM 6 7 10:16AM 8 10:16AM 10:16AM 9 10 10:16AM 11 10:17AM 12 10:17AM 13 10:17AM 14 10:17AM 15 10:17AM 16 10:17AM 17 10:22AM 18 10:22AM 19 10:22AM 20 10:22AM 21 10:22AM 22 10:22AM 10:22AM 23 24 10:22AM 25 10:22AM

10:22AM	1	THE COURT: Go ahead, Mr. Kursman.
10:22AM	2	MR. KURSMAN: That is I think it's more
10:22AM	3	appropriate if they are objected to as offered. We
10:22AM	4	wanted to introduce six of those exhibits prior to
10:23AM	5	offering our witness based on stipulations with
10:23AM	6	Respondents, and those would be Exhibits 6, 7, 8, 9, 10
10:23AM	7	and 11. Respondents agreed to stipulate to the
10:23AM	8	following, that if a record custodian was called to
10:23AM	9	testify, they would testify to the following:
10:23AM	10	That the record was made at or near the
10:23AM	11	time by or from information transmitted by someone with
10:23AM	12	knowledge, that the record was kept in the course of
10:23AM	13	regularly conducted business activity and that making the
10:23AM	14	record was a regular practice of that activity.
10:23AM	15	Respondents also agree to stipulate to the
10:23AM	16	accuracy and authenticity of those exhibits. So
10:23AM	17	Petitioners would move to admit Exhibits 6, 7, 8, 9, 10
10:23AM	18	and 11.
10:23AM	19	THE COURT: Ms. O'Leary.
10:23AM	20	MS. O'LEARY: Respondents do so stipulate
10:23AM	21	and we have no objection to the admission of 6 through
10:24AM	22	10.
10:24AM	23	THE COURT: Through 11.
10:24AM	24	MS. O'LEARY: I'm sorry; was it 11?
10:24AM	25	THE COURT: I heard Mr. Kursman offering 6,

1 10:24AM 2 10:24AM 3 10:24AM 4 10:24AM 5 10:24AM 10:24AM 6 7 10:24AM 8 10:24AM 10:24AM 9 10 10:24AM 11 10:24AM 12 10:24AM 13 10:24AM 14 10:24AM 15 10:24AM 16 10:24AM 17 10:24AM 18 10:25AM 19 10:25AM 20 10:25AM 21 10:25AM 22 10:25AM

23

24

25

10:25AM

10:25AM

10:25AM

MR. KURSMAN: Yes. No. 11, Ms. O'Leary, is the TDCJ protocol.

7, 8, 9, 10 and 11.

MS. O'LEARY: I'm sorry; I didn't see that one. TDCJ's execution procedure, may I ask if it's the current version, revision?

MR. KURSMAN: Yes, Ms. O'Leary. It's the version that was sent to us pursuant to the requests.

MS. O'LEARY: We have no objection to admission of No. 11 then.

THE COURT: All right. Then Petitioner's Exhibits 6 through 11 are admitted without objection. agree that the rest -- if you don't have agreements on them, let's just take up your objections to any other exhibits as they come up.

MS. O'LEARY: Yes, Your Honor.

The other issue, before the Petitioners put on their expert, is we have some argument to make as to why the Court doesn't need to consider the expert's opinion on the factual issues in the case. So if the Court is amenable, I'm happy to present that right now.

THE COURT: Well, yes, go ahead and do that, then I'm going to ask for brief openings. I've reviewed I believe almost all the pleadings, almost all of them. And again, apologies that this came up in the

10:25AM **4**

10:25AM **5**

10:25AM 6

10:25AM **7**

10:25AM 8

10:25AM 9

10:25AM 10

10:26AM 11

10:26AM 12

10:26AM 13

10:26AM 14

10:26AM 15

10:26AM 16

10:26AM 17

10:26AM 18

10:26AM 19

10:26AM 20

10:26AM 21

10:26AM 22

10:26AM 23

10:26AM 24

10:26AM 25

middle of -- I was moving yesterday, so I didn't have much technology set up. I'm going to try to read all of the pleadings.

So let's go ahead and start with that argument, Ms. O'Leary.

MS. O'LEARY: Yes, Your Honor. The Petitioners intend to introduce expert testimony from I'll just say a pharmaceutical expert to discuss expiration dates and beyond-use dates of the drug that TDCJ uses for lethal injection. The Court does not need to get into the question of whether the drugs are, quote, expired or whether they are being used beyond-use date, which is contested.

But even if, for argument's sake, the Court assumes that the drugs are expired or are being used beyond the beyond-use date -- the Court can assume that to be true -- but first the Court should instead recognize that the Petitioners haven't stated a cause of action here. And so even if factually there's a factual dispute or assumption that the asserted facts are true, without a cause of action the Court can't issue an injunction here and no declaratory relief is available.

This is an ultra vires action against TDCJ officials. The basis of the ultra vires asserted conduct is they have violated certain state statutes such as the

1 10:26AM 10:26AM 2 3 10:27AM 4 10:27AM 5 10:27AM 10:27AM 6 7 10:27AM 8 10:27AM 10:27AM 9 10 10:27AM 11 10:27AM 12 10:27AM

10:27AM 13
10:27AM 14
10:27AM 15
10:27AM 16

10:27AM 17
10:27AM 18

10:27AM 19

10:27AM 20

10:27AM **21**

10:28AM 22

10:28AM 23

10:28AM 24

10:28AM 25

Texas Pharmacy Act. As we have laid out in our briefing, none of the statutes that the Petitioners have cited actually apply to TDCJ's use of pentobarbital lethal injection; they simply don't apply. They also cite things like the Texas Penal Code. There's clear exceptions to each of those statutes that exempt TDCJ or exempt this situation from those standards. And so without demonstrating that there's a potential, at least a potential ultra vires claim here, there's no reason to get into the factual disputes about whether the drugs are beyond a beyond-use date.

And I'm happy to go through each of those state statutes if the Court wants to hear that now, and that includes the Texas Pharmacy Act, the Texas Controlled Substance Act, the Penal Code and the Texas Food, Drug and Cosmetics Act.

THE COURT: Mr. Kursman, you want to respond to that, please.

MR. KURSMAN: Sure, Your Honor.

So all of those issues were briefed in our initial petition in Respondents' response and in our reply. I think we can get into those in more detail after Dr. Almgren testifies if Your Honor would like, but I think those are pretty well-briefed in all of our pleadings.

Ms. O'Leary began with saying that we 1 10:28AM didn't state a cause of action, but then describes the 2 10:28AM cause of action that we stated in our petition. And I'm 3 10:28AM sure Your Honor is fully aware of what that is, as we 4 10:28AM filed that petition weeks ago. 5 10:28AM THE COURT: Yes, I am. I've read your 10:28AM 6 7 petition. 10:28AM So that objection is overruled, 8 10:28AM Ms. 0'Leary. All right. 10:28AM 9 Then let's begin, Mr. Kursman, or whoever 10 10:28AM is going to make argument with brief opening statements. 11 10:28AM 12 MR. KURSMAN: Sure, Your Honor. 10:28AM The Texas Department of Criminal Justice 13 10:28AM planned to administer expired drugs to Petitioners 14 10:28AM Fratta, Ruiz, Balentine and Brown during their 15 10:28AM These drugs expired anywhere from 630 days executions. 16 10:28AM ago to over 1,300 days ago. You will hear that when 17 10:29AM drugs are this old the pharmacological property of the 18 10:29AM 19 drugs themselves change. So although the drugs may be 10:29AM labeled pentobarbital, because they are hundreds or 20 10:29AM thousands of days past their expiration date, the 21 10:29AM pharmacological effects of those drugs may not be 22 10:29AM pentobarbital at all. 23 10:29AM You will also hear when drugs are this old 24 10:29AM there's a high risk that they fall out of solution. What 25 10:29AM

10:29AM 2 3 10:29AM 4 10:29AM 5 10:29AM 10:29AM 6 7 10:29AM 8 10:30AM 10:30AM 9 10 10:30AM 11 10:30AM 12 10:30AM 13 10:30AM 14 10:30AM 15 10:30AM 16 10:30AM 17 10:30AM 18 10:30AM 19 10:30AM 20 10:30AM 21 10:30AM 22 10:31AM 10:31AM 23

24

25

10:31AM

10:31AM

1

10:29AM

this means is that the drug themselves become grainy. So instead of injection of a liquid into a vein, the drug themselves will contain solid particles, and when injected into one of the prisoner's veins, it will cause burning at the injection site. Because of these risks the Texas statutes that we outlined in our petition protect against administering expired drugs to humans. Under the statutes in Texas outlined in our petition, it is unlawful to administer expired drugs to human beings.

TDCJ acknowledges that these statutes exist, they implicitly concede that these drugs are expired, but they claim to be above the law. They say that these statutes don't apply to them because the drugs are being used for an execution. There is no legal support for that argument. TDCJ and individuals who work for TDCJ are not above the law. They, too, must follow the laws of practice, even during an execution.

After hearing the evidence this Court should grant a temporary injunction prohibiting TDCJ from administering expired drugs to Messrs. Fratta, Ruiz, Balentine and Brown.

THE COURT: Thank you.

Ms. O'Leary.

MS. O'LEARY: Your Honor, I just want to comment, Mr. Kursman is asking for relief for Mr. Ruiz

and Balentine. We have not been noticed on their 1 10:31AM petition for today's hearing; we've only been noticed on 10:31AM 2 Mr. Fratta's request for temporary injunction. 10:31AM 3 think that their idea of what this hearing is covering is 4 10:31AM different from ours. And I just, again I ask for clarity 5 10:31AM from the Court on whether we are hearing the original 10:31AM 6 7 petition today, which again was not noticed. 10:31AM Well, I think the amended THE COURT: 8 10:31AM request -- I should have -- I skipped over attorney for 10:31AM 9 Mr. Fratta, Mr. Schardl. I should let him speak, as 10 10:31AM But so I think the -- what was noticed is clearly 11 10:31AM 12 we wouldn't be here but for the original petition; it's 10:31AM the underlying pleadings. I'm willing to hear all of it. 13 10:31AM I'm going to let Mr. Kursman, participate; Mr. Schardl, 14 10:31AM as well. 15 10:31AM I guess I should let you go ahead and make 16 10:32AM a statement before Ms. O'Leary goes on. 17 10:32AM 18 MR. SCHARDL: Thank you very much, Your 10:32AM 19 I have nothing to add to what Mr. Kursman said or 10:32AM to what the Court just said. 20 10:32AM THE COURT: Thank you. 21 10:32AM All right, Ms. O'Leary. 22 10:32AM MS. O'LEARY: Yes, Your Honor. 10:32AM 23 important to be aware of the context and timing in which 24 10:32AM

25

10:32AM

we find ourselves in court today. Mr. Fratta's death

1 10:32AM 10:32AM 2 10:32AM 3 4 10:32AM 5 10:32AM 10:32AM 6 7 10:32AM 8 10:32AM

10:32AM 9
10:32AM 10
10:33AM 11
10:33AM 12

10:33AM

10:33AM

13

14

10:33AM 15
10:33AM 16

10:33AM 18
10:33AM 19

10:33AM **21**

10:33AM 22

10:33AM 23

10:33AM 24

10:33AM 25

sentence became final in 2011. TDCJ has been using compounded single drug pentobarbital for lethal injection since 2013, using the current testing and retesting processes that are currently in place since 2013. So at any time over the past nine years the Petitioners could have raised this claim; but instead we find ourselves in a hearing hours before Mr. Fratta's scheduled execution.

It's also important to note that there's an active writ of prohibition in the case that prevents -- it orders this Court to refrain from issuing any order purporting to stay an execution. And even if an order doesn't say that it stays an execution, it can have that effect; and so we just want to point out that is still in place.

And again, the Court doesn't need to go into the factual assertions in the case because the Petitioners haven't demonstrated a cause of action. They wrote ultra vires on their petition; so they have picked out a cause of action, but they haven't asserted any facts that would allow this Court to find that any official acted in an ultra vires manner.

An ultra vires action cannot lie where there is discretion. The Respondents are statutorily required to carry out lethal injection, and that is in the Code of Criminal Procedure. The statute gives

1 10:33AM 10:33AM 2

3 10:33AM 4 10:33AM 5

10:34AM

10:34AM

10:34AM

10:34AM 6

7

8 10:34AM

10:34AM 9 10

11 10:34AM

12 10:34AM

13 10:34AM

14 10:34AM

15 10:34AM

16 10:34AM

17 10:34AM

18 10:34AM

19 10:34AM

20 10:35AM

21 10:35AM

22 10:35AM

23 10:35AM

24 10:35AM

25 10:35AM

Director Bobby Lumpkin discretion in deciding how to carry out lethal injection.

The State is indeed regulated on how it carries out a lethal injection and it is regulated by the 8th Amendment, which is not a cause of action that's been raised here. It is not regulated by things like the Texas Pharmacy Act or the Food, Drug and Cosmetic Act.

Petitioners allege that Respondents have violated the Texas Pharmacy Act. If the Court looks at the statute, it describes who the statute applies to. The pharmaceutical standards are codified in Texas law and again, they specify who they apply to. They do not apply to TDCJ, its officials or lethal injection.

For example, the Texas Pharmacy Acts states it applies to a provider prescribing a medication to a That's obviously something that doesn't apply patient. And right in the introduction of the Texas here. Pharmacy Act it says that it, "Regulates the practice of pharmacy and licensing pharmacies that are engaged in distribution of prescription drugs and devices that are used in diagnosing illness, injury or disease."

That is not something that is happening when TDCJ is carrying out lethal injection. treating anything, we're not providing any kind of therapeutic treatment or drugs. We're not treating

1 10:35AM 10:35AM 2 3 10:35AM

4 10:35AM

10:35AM

10:35AM 6

5

7

10

10:35AM 8 10:35AM

10:35AM 9

10:35AM

11 10:35AM

12 10:35AM

13 10:35AM

14 10:35AM

15 10:36AM

16 10:36AM

17 10:36AM

18 10:36AM

19 10:36AM

20 10:36AM

21 10:36AM

22 10:36AM

10:36AM 23

24 10:36AM

25 10:36AM

illness, injury or disease. And so right from the introduction of the Pharmacy Act, it's clear that it does not apply to TDCJ.

The Texas Controlled Substances Act. there's a clear exception that involves the licensing to possess controlled substances. There's a clear exception for employees of the State engaged in the enforcement of law or carrying out an official duty.

Additionally, TDCJ has a DEA license to possess pentobarbital. The Petitioners have copies of the DEA order forms they appended back to their original petition. So for those reasons, the Controlled Substances Act doesn't apply to TDCJ.

The Texas Food, Drug and Cosmetic Act is a consumer protection statute. It regulates labelling, branding and other safety mechanisms for products that are introduced into commerce. That is not what is happening in lethal injection. We don't need to be concerned with consumers who are reading the labels on lethal doses of pentobarbital.

And lastly, Petitioners allege that TDCJ officials are violating the Penal Code because they are bringing a controlled substance into a correctional There is a clear exception in the Penal Code facility. for officials carrying out legal duties, and they have a 10:36AM 1

10:36AM 3

10:36AM 4

10:36AM 5

10:36AM 6

10:36AM 7

10:37AM 8

9

10:37AM

10:37AM 10

10:37AM 11

10:37AM 12

10:37AM 13

10:37AM **14**

10:37AM 15

10:37AM 16

10:37AM **17**

10:37AM 18

10:37AM 19

10:37AM 20

10:37AM **21**

10:37AM 22

10:37AM 23

10:37AM 24

10:37AM 25

legal duty here. There is a valid court order issuing a death warrant and there's a statute that says TDCJ shall carry out lethal injection.

Similar challenges have been raised in the federal courts, as we've laid out in our briefing. The Fifth Circuit has repeatedly rejected challenges to TDCJ's use of pentobarbital, including challenges that allege that pentobarbital is expired. Those have been rejected by the Fifth Circuit.

To be entitled to injunctive relief the Petitioners have to prove three elements, the first of which is they have to show that they have a cause of action. For the reasons I've just said and for the reasons laid out in our brief, they haven't satisfied the first element or the second element, which is that they have a probable right to relief.

The last element is they have to show a probable imminent irreparable injury. Now, you're going to hear evidence from their -- or testimony from their expert talking about what may happen, what she thinks will happen. She applies pharmaceutical standards in reaching those conclusions. And as I've just discussed, the pharmaceutical standards in the USP do not apply to this situation because we're not treating injury, illness or disease.

1 10:37AM 10:37AM 2 3 10:38AM 4 10:38AM 5 10:38AM 10:38AM 6 7 10:38AM 8 10:38AM 10:38AM 9 10 10:38AM 11 10:38AM 12 10:38AM 13 10:38AM 14 10:38AM 15 10:38AM 16 10:38AM 17 10:38AM 18 10:38AM 19 10:39AM

And lastly, Your Honor, because this is a challenge to the method of execution, the United States Supreme Court has added another standard on top of the injunctive relief standard that the Petitioners have to meet, and that is found in Blaze vs. Rees. The Petitioners have to show that the State's lethal injection creates a demonstrated risk of severe pain.

Your Honor, the TDCJ has carried out executions using pentobarbital under the same testing process that it uses now over 70 times. It has carried out lethal injection over 90 times. What the Petitioners describe has never happened; it simply has never happened. The drugs that TDCJ possesses and uses and sends to labs to get tested are -- and the Petitioners' own evidence shows that it was retested as recently as January of 2022 -- it's proven to be potent and effective.

The other factors that might be relevant to therapeutic uses of drugs simply don't matter for purposes of a lethal injection. And for that reason we believe that their request for injunctive relief and declaratory relief should be denied.

THE COURT: Thank you. All right. Well, before we begin, I'm certainly aware of the Court of Criminal Appeals order and I understand that I am

20

21

22

23

24

10:39AM

10:39AM

10:39AM

10:39AM

10:39AM

10:39AM	1	prohibited from issuing any order that purports to stay
10:39AM	2	the scheduled executions, and I would not assume to do
10:39AM	3	so. This is a separate matter having to do with an
10:39AM	4	injunction on the use of what the Plaintiffs allege are
10:39AM	5	expired drugs that do not meet certain standards set out
10:39AM	6	in various civil statutes, so we'll proceed with that
10:39AM	7	evidence.
10:39AM	8	Mr. Kursman, if you would like to call your
10:39AM	9	first witness.
10:39AM	10	MR. KURSMAN: Thank you, Your Honor.
10:39AM	11	Before I do, could I just ask that we be given time to
10:39AM	12	respond to Ms. O'Leary's legal arguments?
10:39AM	13	THE COURT: Yes, go ahead. After you
10:40AM	14	want to call your witness yes.
10:40AM	15	MR. KURSMAN: Petitioners call Dr. Michaela
10:40AM	16	Almgren.
10:40AM	17	MICHAELA ALMGREN,
10:40AM	18	having been duly first sworn, testified as follows:
10:40AM	19	DIRECT EXAMINATION
10:40AM	20	BY MR. KURSMAN:
10:40AM	21	Q. Dr. Almgren, can you introduce yourself to the
10:40AM	22	Court.
10:40AM	23	A. So my name is Michaela Almgren. I'm a clinical
10:40AM	24	associate professor of pharmacy at the University of
10:40AM	25	South Carolina College of Pharmacy. I'm a licensed
		\boldsymbol{i}

10:40AM 1

10:40AM 3

10:40AM 4

10:40AM 5

10:40AM 6

10:41AM **7**

10:41AM 8

10:41AM 9

10:41AM 10

10:41AM 11

10:41AM 12

10:41AM 13

10:41AM **14**

10:41AM 15

10:41AM 16

10:41AM 17

10:41AM 18

10:41AM 19

10:41AM 20

10:41AM 21

10:41AM 22

10:41AM 23

10:42AM 24

10:42AM 25

pharmacist in South Carolina and a few other states and I have really vast experience in sterile compounding.

When I was a student I was a pharmacy technician working in a hospital performing sterile compounding. When I graduated I was a pharmacist in a large teaching hospital performing duties of a sterile compounding pharmacist. I worked in oncology, I worked in home infusion, all of those fields involving sterile compounding.

I also teach CE, continuing educational courses to pharmacists that deal with this subject matter of sterile compounding. I'm very familiar with sterile compounding under 503A regulations. And most recently I became a pharmacist as a part of my clinical assignment with the university as a 503B pharmacy. And so I also have vast experience now in sterile compounding regulations as they are related to 503B pharmacy.

I also have pharmaceutical industry experience because prior to going to pharmacy school I actually went to -- I worked for a number of drug companies and I worked as an analytical chemist. So I have this analytical chemistry experience, I have a master's degree -- I have a college degree in biology and chemistry. I have a master's degree in pharmaceutical sciences in pharmacy and I also have a doctorate in

0:42AM 1 | pharmacy.

- Q. And Dr. Almgren, can you just briefly describe for the Court what a pharmacist does?
- A. So it really depends, because the area of pharmacy practice is very vast. So you can be a clinical pharmacist working in a hospital, you can be a retail pharmacist working in Rite Aid or a Walgreen's dispensing and working directly with the public. My area of expertise is sterile compounding and so what I do is, I prepare medications based on physicians' orders for patients.
- Q. Can you tell the Court what sterile compounding means?
- A. So sterile compounding involves preparation of drugs where you start with either a sterile drug -- this would be considered low risk compounding where you start with maybe a vial of drug that comes from the manufacturer and, according to the doctor's orders, you will perhaps dilute the medication or maybe turn it from an injection into an infusion. So you are going to add it to an IV bag. So that would be considered low risk compounding.

Then you have a medium risk compounding that involves more complex procedures. So if I was compounding a total parenteral nutrition product, so

10:42AM 10:42AM 16 10:42AM 17 10:43AM 18 10:43AM 19 10:43AM 20 10:43AM 21 10:43AM 22 10:43AM

10:43AM

10:43AM

10:43AM

23

24

25

10:43AM 1 10:43AM 2

10:43AM 3

10:43AM 4

10:43AM 5

10:43AM 6

10:43AM **7**

10:43AM 8

10:43AM 9

10:44AM 10

10:44AM 11

10:44AM 12

10:44AM 13

10:44AM **14**

10:44AM 15

10:44AM 16

10:44AM 17

10:44AM 18

10:44AM 19

10:44AM 20

10:44AM 21

10:44AM 22

10:44AM 23

10:44AM 24

10:44AM 25

something that contains a number of additives -- so maybe I'll add 10 or 12 additives -- that would be considered a medium risk compounding.

Then there is high risk compounding. And according to USP 797, the guidance that basically provides all of the regulations for 503A pharmacies in regards to sterile compounding, the high risk compounding involves starting with a nonsterile product that would be maybe an API active pharmaceutical ingredient that you will weigh out, measure out in some way and then you're going to dilute it and prepare a sterile product basically by sterilizing it. You prepare it, you maybe add an additive or two and then you go in to either filter, sterilize it, make it sterile or you could autoclave it, depending on the product itself.

- Q. Do you also have experience with extending beyond-use dates of --
 - A. Yes.
 - Q. -- medications?
- A. Yes, I do. Of course, in a 503B environment we have to follow CGAP regulations, so we extend beyond-use dates according to that. I also worked in a hospital teaching pharmacy, and so we extended beyond-use dates according to USP 797.
 - Q. Did you prepare a CV in connection with this

case? 1 10:44AM I'm sorry; you broke up. 2 Α. 10:44AM Did you prepare a CV in connection with this Q. 3 10:44AM case? 4 10:44AM Yes, I did. Yes, I'm sorry. 5 Α. 10:44AM I'm going to show you what's marked as Q. 10:45AM 6 Petitioner's Exhibit 1. 7 10:45AM MS. O'LEARY: Your Honor, Respondents 8 10:45AM object to Exhibit 1 as hearsay. 10:45AM 9 THE COURT: Mr. Kursman. 10 10:45AM Your Honor, because this is a MR. KURSMAN: 11 10:45AM 12 bench preliminary injunction hearing, we were thinking 10:45AM that it would be -- it would streamline both this 13 10:45AM presentation and whatever argument happens later on on 14 10:45AM Ms. Almgren's expertise, but we're happy to just go 15 10:45AM further through Ms. Almgren's expertise. 16 10:45AM THE COURT: That's all right, no. The 17 10:45AM objection will be overruled and the CV will be admitted. 18 10:45AM 19 Q. (Mr. Kursman) Dr. Almgren, are you familiar 10:45AM with the United States Pharmacopeia? 20 10:45AM Yes, of course. It's a -- basically it governs 21 Α. 10:46AM a lot of the pharmacy practice, pharmaceutical industry. 22 10:46AM It's a really excellent reference for practice. 10:46AM 23 And can you tell the Court why it's important 24 Q. 10:46AM for a pharmacist to be familiar with the United States 25 10:46AM

0:46AM 1 Pharmacopeia?

O:46AM 2 A. You

3

4

5

6

7

8

9

10

11

12

A. You must be familiar with the USP because it basically provides guidance on our everyday activities; everything from how we compound, how we handle medications, storage conditions. A lot of really good references is in USP.

- Q. Are you familiar with USP Chapter 797?
- A. Yes, absolutely. It is a subject matter that I have been teaching for years. And USP Chapter 797 basically governs or provides guidance on how to perform sterile compounding in 503A regulated environment.
 - Q. And are you familiar with USP Chapter 790?
- A. Yes, absolutely. USP Chapter 790 describes how to perform visual inspection for injectables.
 - Q. And are you familiar with USP Chapter 71?
- A. Yes. Yes, that's another very good compounding method that describes how to perform sterility testing on the products that are compounded.
- Q. Dr. Almgren, have you served as an expert in litigation before, an expert in pharmacy?
 - A. Yes.

MR. KURSMAN: Your Honor, we would move to have Dr. Almgren qualified as an expert in pharmacy compounding, United States Pharmacopeia and extending beyond-use dates.

10:46AM
10:46AM
10:46AM
10:46AM
10:46AM
10:46AM
10:46AM
10:46AM
10:46AM

10:46AM 13

10:47AM 15

10:47AM 16

10:47AM **17**

10:47AM 18

10:47AM 19

10:47AM 20

10:47AM 21

10:47AM 22

10:47AM 23

10:47AM 24

10:47AM **25**

10:47AM	1	THE COURT: She's so accepted. You may
10:47AM	2	proceed.
10:47AM	3	Q. (Mr. Kursman) Dr. Almgren, were you retained
10:47AM	4	in this case by Petitioners' counsel?
10:47AM	5	A. Yes.
10:47AM	6	Q. Were you asked to provide an opinion about this
10:47AM	7	case?
10:47AM	8	A. Yes.
10:47AM	9	Q. Can you tell the Court what you were asked to
10:48AM	10	provide an opinion about?
10:48AM	11	A. So I was provided a number of documents to
10:48AM	12	review and basically assess whether the beyond-use date
10:48AM	13	on the products that I used are is appropriate.
10:48AM	14	Q. Were you asked to reach a conclusion about
10:48AM	15	whether the pentobarbital in TDCJ's possession is
10:48AM	16	expired?
10:48AM	17	A. Yes, I was asked to analyze and basically see
10:48AM	18	if I what are my thoughts on the expiry of those
10:48AM	19	products, yes.
10:48AM	20	Q. And what is your opinion on whether the
10:48AM	21	pentobarbital in TDCJ's possession is expired?
10:48AM	22	A. Those products are well beyond expiry. The way
10:48AM	23	that the TDCJ extends beyond-use dating is not
10:48AM	24	appropriate. This is not how you are supposed to extend
10:48AM	25	beyond-use dating on drugs.

10:48AM	3
10:49AM	4
10:49AM	5
10:49AM	6
10:49AM	7
10:49AM	8
10:49AM	9
10:49AM	10
10:49AM	11
10:49AM	12
10:49AM	13
10:49AM	14
10:49AM	15
10:49AM	16
10:49AM	17
10:49AM	18
10:49AM	19
10:49AM	20
10:49AM	21
10:49AM	22
10:50AM	23
10:50AM	24
10:50AM	25

1

2

3

10:48AM

10:48AM

10 · /8AM

- Q. Do you hold that opinion to a reasonable degree of scientific certainty?
 - A. Absolutely.
- Q. Can you tell the Court what documents you reviewed to come to that opinion?
- A. So I looked at the -- I guess the documents are listed in my testimony, in my report. But some of the key documents that I looked at were some of the analytical reports that were provided that basically show the potency and some of the testing results of the drugs, as well as I reviewed I guess the storage logs for the drugs themselves.
- Q. Were you also asked to opine on whether there was a risk of harm that can be caused by the administration of the expired compounded pentobarbital?
 - A. Yes, that's correct.
 - Q. Did you provide an opinion?
 - A. I did.
- Q. And can you describe for the Court what that opinion is?
- A. Well, the drugs that are currently in possession, as far as I know from the records that I was provided, all appear to be well-beyond expiry, well beyond expiration date. And with those types of medications, it's really difficult to tell what the

10:50AM 2
10:50AM 3

10:50AM

10:50AM 5
10:50AM 6

4

9

10:50AM 7
10:50AM 8

10:50AM 10

10:50AM

10:50AM 11

10:50AM 12

10:51AM 13

10:51AM 14

10:51AM 15

10:51AM 16

10:51AM 17

10:51AM 18

10:51AM 19

10:51AM 20

10:51AM 21

10:51AM 22

10:51AM 23

10:51AM 24

10:51AM 25

pharmacological activity would be. Typically when you have medications that expired, the further away they are from the date when they were prepared, the more chances there are that the medication will not work as expected.

I looked at the data related to the pentobarbital and I saw how the TDCJ is trying to extend the beyond-use date using the assay testing, but that is not appropriate; and actually the potency of the drug might be much lower than what was determined, and so the potency may be affected. Typically as the medication sits for a long time -- and of course I'm not sure, but it does not appear that the storage conditions are really well-monitored for those medications.

That also brings up another concern, because medications, if they are stored in conditions where the temperature changes, humidity changes, they may be exposed to light; all of that has impact on medication quality. And of course, the medications are expired, to begin with, and then they are, you know, exposed to all of these unknown conditions. So the chances of those medications not functioning as they are supposed to are really high.

- Q. Is one of the probable risks that the drugs will fall out of solution?
 - A. There is a good probable. The reason for that

1 10:51AM

soluble, so it is not your typical type of medication. 10:51AM 2

3 10:51AM

People think, oh, you just take the vial, add some normal

Pentobarbital is actually not water

is the medication itself, pentobarbital, is not water

4 10:51AM

saline, dissolve it; here it is in liquid and you go

5 10:51AM

ahead and inject it.

10:51AM

6

9

soluble. So what you have to do is, you have to adjust 10:51AM 7

8 10:52AM

the pH of the solution and you have to dissolve the

10:52AM

pentobarbital powder in alcohol, and so this way you are

10 10:52AM

making it to come into the solution. But what happens in

11 10:52AM

time is the pH will shift because of, like I said, the

12 10:52AM

environmental exposure, just time itself; also alcohol,

13 10:52AM

as we all know, will evaporate over time.

14 10:52AM

concentration of that will shift, as well, and all of

15 10:52AM

that can potentially lead to the drug degrading, coming

16 10:52AM

out of solution.

10:52AM

I would like to see the vials of the drug. 17

18 10:52AM

I have no doubt that every one of them have changed color

19 10:52AM

from the original. You know, it's supposed to be clear

20 10:52AM

colored solution. You know, looking at the records that

21 10:52AM

I was provided, I have no doubt at all that those vials

22 10:52AM

are probably yellow by now, and that just shows the signs

23

10:52AM

of degradation.

24 10:52AM

And if the drug falls out of solution, does Q.

25 10:52AM

that cause pain at the injection site?

1 10:52AM 10:53AM 2 3 10:53AM 4 10:53AM 5 10:53AM 10:53AM 6 7 10:53AM 8 10:53AM 10:53AM 9 10 10:53AM 11 10:53AM 12 10:53AM 13 10:53AM 14 10:53AM 15 10:53AM 16 10:53AM 17 10:53AM 18 10:54AM 19 10:54AM 20 10:54AM 21 10:54AM 22 10:54AM 10:54AM 23 24 10:54AM

25

10:54AM

A. Oh, absolutely. Medications, if there is any precipitation -- this is the whole point of USP Chapter 790. You perform visual inspection to make sure that the medications do not have any precipitant form in them. Because if you inject medication that has particulate matter in them, if you inject them intravenously, it definitely can cause pain, burning at injection site. A lot of times you will have occlusion of the blood vessels and that can cause severe pain.

I have read literature because I do a lot of assessments, clinical assessments for my 503B pharmacy appointment. So I a lot of times assess clinical risks of medication that contains particulate matter, and they can have very severe outcomes. Patients can get a stroke, embolism, those types of things from having particulates in a solution.

Q. I'm going to show you what's marked as Plaintiff's Exhibit 2. Do you recognize this exhibit?

A. Yes.

MS. O'LEARY: Respondents object to this exhibit, Your Honor. It is inadmissible hearsay. Expert reports are typically inadmissible without a non-hearsay purpose, and this doesn't fall within any of the exclusions or exceptions in Rule 801 or 803.

In re: Commitment of Johnson, Delamar vs.

Regardless

Fort Worth Mountain Bikers Association, these are just a 1 10:54AM handful of cases that exclude expert reports. 10:54AM 2 of whether the expert is testifying, the report itself is 3 10:54AM hearsay. 4 10:54AM THE COURT: Mr. Kursman. 5 10:54AM MR. KURSMAN: Your Honor, we are just 10:54AM 6 7 attempting to streamline this presentation because 10:54AM there's not a jury; but, of course, we are willing to 8 10:54AM just go into the details of the report rather than enter 10:54AM

it, if you would like.

THE COURT: The objection is sustained.

- Q. Aside from the documents that you discussed earlier that you relied on, did you rely on any scientific sources in coming to your conclusions?
- Absolutely. This is typically what I do. Ι mean, I have a lot of experience working in analytical chemistry for almost ten years and working in industry and working in a pharmacy. I do have vast experience, but I typically prefer to find scientific arguments that will support, you know, whatever my findings are.
- Q. I'm going to show you what's marked as Plaintiff's Exhibit 3. Do you recognize Plaintiff's Exhibit 3?
 - Yes, that's USP Chapter 797. Α.

MS. O'LEARY: Your Honor, Respondents

10 10:54AM 11 10:54AM 12 10:55AM

14 10:55AM 15 10:55AM 16 10:55AM

10:55AM

13

17 10:55AM 18 10:55AM 19 10:55AM

20 10:55AM 21 10:55AM

22 10:55AM

23 10:55AM

24 10:55AM

25 10:55AM

There are

object to Exhibits 3, 4, 5, which are all similar to the 1 10:55AM one that we see here, as hearsay. They also have 10:56AM 2 improper foundation; there's no authentication. 3 10:56AM nothing to show that these standards apply in Texas. 4 10:56AM When Texas has standards, they are codified. 5 10:56AM pharmacy standards codified in the Texas Administrative 10:56AM 6 Code and this is not a copy of the administrative code 7 10:56AM 8 SO... 10:56AM THE COURT: Sorry, Ms. O'Leary. You froze 10:56AM 9 there for a second. You got cut off. 10 10:56AM (Brief pause.) 11 10:57AM 12 MS. O'LEARY: As I was saying, Exhibits 3, 10:57AM 4 and 5, each are inadmissible hearsay, they don't fall 13 10:57AM within one of the exceptions or exemptions, and the 14 10:57AM expert has not linked this to what is applicable in 15 10:57AM Texas, which is found in the Texas Administrative Code. 16 10:57AM MR. KURSMAN: Your Honor, I think if I ask 17 10:57AM another question maybe it would clear this up. 18 10:57AM 19 THE COURT: All right, go ahead. 10:57AM (BY MR. KURSMAN) Is this a source that is 20 Q. 10:57AM ordinarily relied upon by experts in your field? 21 10:57AM Absolutely. This is something that we use 22 Α. 10:57AM across the country. This is something that pharmacists 10:57AM 23 in Texas, South Carolina, anywhere in the United States 24 10:57AM

Yes, this is a very common standard.

25

10:57AM

use.

As a matter of fact, if you work in any 1 10:57AM kind of a health system, pharmacy setting, you have to 2 10:58AM comply with the JCAHO regulations and, of course, this is 3 10:58AM one of the requirements. So this is a very widely 4 10:58AM accepted standard of practice. 5 10:58AM MR. KURSMAN: So we would move to admit 6 10:58AM Exhibit 3 under Rule 703. 7 10:58AM MS. 0'LEARY: The Respondents continue to 8 10:58AM object based on hearsay, Your Honor. 9 10:58AM THE COURT: How do you responded to the 10 10:58AM hearsay objection, Mr. Kursman? 11 10:58AM Your Honor, I believe 12 MR. KURSMAN: 10:58AM Rule 703 allows documents in that experts rely on if it's 13 10:58AM relied upon ordinarily by experts in their field, and 14 10:58AM Dr. Almgren testified it was. So I believe it comes in 15 10:58AM under 703. 16 10:58AM The objection is overruled. THE COURT: 17 10:58AM Exhibit 3 is admitted. 18 10:58AM (Mr. Kursman) Dr. Almgren, let me show you 19 10:58AM what is marked as Plaintiff's Exhibit 4. 20 10:58AM recognize this exhibit? 21 10:59AM Yes, yes. This is USP Chapter 71. It 22 10:59AM describes how to perform sterility tests on products that 10:59AM 23 are sterile compounds. 24 10:59AM Is this a source that is ordinarily relied upon Q. 25 10:59AM

10:59AM	1	by experts in your field?
10:59AM	2	A. Absolutely, yes.
10:59AM	3	MR. KURSMAN: I move to admit Petitioner's
	4	Exhibit 4.
	5	THE COURT: Mr. Marshall, are you taking
	6	over? I don't see Ms. O'Leary.
	7	MR. MARSHALL: Ms. O'Leary is attempting to
	8	restart her computer.
	9	THE COURT: Let's give her a moment to do
10:59AM	10	that.
10:59AM	11	MR. MARSHALL: Your Honor, I'm perfectly
10:59AM	12	willing to follow along with the testimony here. If
10:59AM	13	we're going to examine the witness, I will be the one
10:59AM	14	asking the questions so
10:59AM	15	THE COURT: Well, if you are going to be
10:59AM	16	the one asking the questions, you need to be making the
11:00AM	17	objections; we don't go back and forth. Ms. O'Leary had
11:00AM	18	started with making the objections, so I assumed she
11:00AM	19	would be doing the cross-examination. You don't get to
11:00AM	20	tag team. Let's wait for Ms. O'Leary to get back,
11:00AM	21	please.
11:01AM	22	MS. O'LEARY: I apologize for that.
11:01AM	23	THE COURT: That's all right.
11:02AM	24	Mr. Kursman had offered Exhibit 4.
11:02AM	25	MS. O'LEARY: Your Honor, Respondents

object for the same reasons as 3. 1 11:02AM No. 4 will be admitted. THE COURT: 2 11:02AM (Mr. Kursman) I'm just going to ask is this a Ο. 3 11:02AM source -- I think I did ask while Ms. O'Leary was gone. 4 11:02AM This is a source that is ordinarily relied upon by --5 11:02AM THE COURT: Hold on. Before you go on, I 6 11:02AM 7 can see your the -- there you go. 11:02AM (Mr. Kursman) This is a source that is 8 Q. 11:02AM ordinarily relied upon by experts in your field? 11:02AM Yes. Α. 10 11:02AM MR. KURSMAN: We will move to admit 11 11:02AM Petitioner's Exhibit 4. 12 11:02AM I had just admitted 4 a moment THE COURT: 13 11:02AM You can move on from that. ago. 14 11:02AM (Mr. Kursman) Dr. Almgren, I want to show you Q. 15 11:02AM Petitioner's Exhibit 5. Do you recognize this exhibit? 16 11:02AM Α. Yes, I do. 17 11:03AM Can you describe for the Court what this Q. 18 11:03AM 19 exhibit is? 11:03AM So this is the USP chapter that describes how 20 11:03AM to perform visual inspection for visible particulates in 21 11:03AM the injections. It's very commonly used. We use it in 22 11:03AM the hospital when we examine and prepare medications. 11:03AM 23 I've used it in industry, used it in pharmacy, in 503B 24 11:03AM It's very commonly used by pharmacists. 25 setting. 11:03AM

1 11:03AM 2 11:03AM 3 11:03AM 4 11:03AM 5 11:03AM 6 11:03AM 7 11:03AM 8 11:03AM 9 11:04AM 10 11:04AM 11 11:04AM 12 11:04AM 13 11:04AM 14 11:04AM 15 11:04AM 16 11:04AM 17 11:04AM 18 11:04AM 19 11:04AM 20 11:04AM 21 11:04AM

22

23

24

25

11:04AM

11:04AM

11:04AM

11:04AM

MR. KURSMAN: I would move to admit Petitioner's Exhibit 5.

THE COURT: Ms. O'Leary.

MS. O'LEARY: Respondents object to 5 on the same basis as 3 and 4; hearsay.

THE COURT: No. 5 is admitted.

- Q. (Mr. Kursman) Dr. Almgren, in your initial testimony you described commercially manufactured drugs versus compounded drugs. Can you -- first, is there a difference between the two?
- A. Yes, there is absolutely a big difference between the two. Typically your commercially prepared medications undergo very rigorous testing.

You know, think about medications that are made by Baxter and Pfizer. When they make those, let's say, sterile preparations, they make thousands, tens of thousands of dosages. And so, of course, they have to have a very strict and a good manufacturing control, quality control over their products. You know, the medications are tested multiple times throughout the manufacturing process. At the beginning, throughout you want to assure there is continuity and uniformity that the sterility is tested properly and all that. So the manufacturing process is very strictly controlled. We use CGMP regulations from the FDA that basically oversee

11:05AM **1**

11:05AM 2

11:05AM 3

11:05AM 4

11:05AM **5**

11:05AM 6

11:05AM **7**

11:05AM 8

11:05AM

11:05AM 10

11:05AM 11

11:05AM 12

11:05AM 13

11:05AM **14**

11:05AM 15

11:05AM 16

11:05AM 17

11:06AM 18

11:06AM 19

11:06AM 20

11:06AM 21

11:06AM 22

11:06AM 23

11:06AM 24

11:06AM 25

this process and they are very detailed, very vigorous.

By comparison, when you perform sterile compounding in a 503A setting, let's say in the hospital or in a pharmacy, the 503A compounding does not have those controls in place. All we have is USP Chapter 797, and that is what we follow. And so in Chapter 797, you know, when you read for example how beyond-use dating is established, it's much shorter because you don't have as much control over the compounds as you do when you follow CGMP.

You know, when I teach my pharmacy students I always compare, I tell them, "You know when we talk about USP Chapter 797, it's kind of like the high school level regulations; then when you are looking at the CGMP, it's kind of like the doctorate level regulations." Like they are really strict, very specific, you know, and they are really made to, you know, to promulgate really good control over the entire manufacturing process.

THE COURT: Doctor, let me stop you. Tell me, what does CGMP stand for?

THE WITNESS: Yes, absolutely. So CGMP stands for Current Good Manufacturing Practices, and those are specified in the Food, Drug and Cosmetic Act. I think it's in the Federal Register. Chapter 210, 211 specify specifically sterile compounding practices.

1 11:06AM 2 11:06AM 3 11:06AM 4 11:06AM 5 11:06AM 11:06AM 6 7 11:06AM 8 11:06AM

11:06AM 9
11:07AM 10
11:07AM 11

11:07AM 14

11:07AM

13

18

11:07AM 16

11:07AM

11:07AM 19
11:07AM 20

11:07AM 21

11:07AM 23

11:07AM 24

11:07AM 25

And like I said, the CGMP, the Current Good Manufacturing Practices are practices that are implemented by pharmaceutical manufacturers and also 503B compounders, so both of those. Because of the sizes of batches, you have to have a much more strict control over your process, over your compounding or manufacturing process because your medications go to thousands of patients.

So on the other end of the spectrum you have USP Chapter 797 that provides you the basics on how to perform compounding, sterile compounding, to prepare safe drugs for individual patients.

- Q. (Mr. Kursman) Does USP also describe how to extend the beyond-use dates of compounded drugs?
 - A. It does touch upon that, yes.
- Q. And does it also describe what the beyond-use date of compounded drugs would be?
- A. Yes, absolutely. And this is very crucial because, again, when you think about manufacturing you have so many controls in place; with compounding you don't. It's really the pharmacist or the pharmacy technician who is compounding, so those beyond-use dates will be much shorter than your traditional expiry of the manufactured medications. You know, by comparison manufactured drugs, they may have expired a couple of

years, two to three years. 1 11:07AM

> I work for a 503B compounding drug company and so we perform compounding under 503B regulations. we follow CGMP, and none of our beyond-use dates are past 180 davs. So even though we have strict control over our process, we still don't extend the beyond-use date past 180 days, just out of caution.

> And then you have USP Chapter 797 that, again as I said, the regulations are different and the control of the process of the compounding isn't as good because, as I said, those are small batches typically made for one or two patients by pharmacists in a It's not your big, you know, manufacturing, hospital. automated system where there is very little human The compounding is all human interaction, interaction. so a lot of potential for error, a lot of potential for So because of that, your beyond-use dates contamination. are going to be significantly shorter; typically in days or hours.

- And are the drugs in TDCJ's possession Q. commercially manufactured drugs or are they compounded drugs?
- They are compounded drugs. That's what it says Α. in their records.
 - And what does it mean for a drug to be Q.

11:07AM 2 3 11:08AM 4 11:08AM 5 11:08AM 11:08AM 6 7 11:08AM 8 11:08AM 11:08AM 9 10 11:08AM

11 11:08AM 12 11:08AM 13 11:08AM

15 11:08AM

11:08AM

11:08AM

14

16 11:08AM 17

18 11:09AM

19 11:09AM

20 11:09AM

21 11:09AM

22 11:09AM

11:09AM 23

24 11:09AM

25 11:09AM

compounded?

That basically means that it was probably a pharmacist or pharmacy technician who prepared it. not commercially manufactured, an automated system.

- And are these sterile compounded drugs? Q.
- They need to be sterile because they are going to be injected into a patient. So, of course, they need to be sterile.
- According to the USP, what is the maximum beyond-use date for a sterile compounded drug?
- So according to USP Chapter 797, if you keep the medication deeply frozen -- so that means it's in a minus 10 to minus 25 degree type of deep freeze setting -- it is good for 45 days.
- And the three exhibits I showed you previously, Exhibits 3, 4 and 5, which were USP 797, 790 and 71, are those guidelines that pharmacists follow when performing sterile compounding of drugs?
 - Α. Yes. Yes, of course.
- Are the vials of pentobarbital in TDCJ's Q. possession considered high risk sterile compounds?
- My assumption is that they are high risk Α. compounds, yes.
 - Can you tell the Court why? Q.
 - Because they are most likely -- they have been Α.

- 1
- 2 11:09AM 3 11:09AM 4 11:09AM 5 11:09AM 6 11:09AM

11:09AM

- 7 11:09AM 8 11:09AM
- 10 11:09AM

11:09AM

11:09AM

9

11

- 12 11:09AM 13 11:10AM
- 14 11:10AM
- 15 11:10AM 16 11:10AM
- 17 11:10AM
- 18 11:10AM
- 19 11:10AM
- 20 11:10AM
- 21 11:10AM
- 22 11:10AM
- 11:10AM 23
- 24 11:10AM
- 25 11:10AM

prepared from the API, from the powdered drug. So if you 1 are starting with an API that's typically nonsterile, you 2 are going to weigh out the medication, you are going to 3 prepare the solution. As I described earlier, this is a 4 non-water soluble drug, so more technically advanced in 5 terms of how you prepare it. And so the medication is 6 prepared and then put in the vials, and so then it has to 7 be sterilized prior to being put in vials. 8

- And I believe you testified this a minute ago Q. about all compounded drugs, but what is the maximum beyond-use date for high risk sterile compounds?
- Α. It is the same. It's 45 days. So 45 days in deep freeze, yes.
 - And what if they are not in deep freeze? Q.
- Then, depending on the storage conditions, 24 hours if they are stored in room temperature -- that's for high risk compounds -- and 72 hours, or 3 days, if they are stored in refrigerator.
- And what chapter of the USP should be followed for compounding of high risk sterile compounds?
 - It's USP Chapter 797. Α.
- I'm going to show you again Plaintiff's Q. Exhibit 3. And is this USP 797 we are looking at right here?
 - Yes, it is. Α.

11:10AM 11:10AM 11:10AM 11:10AM 11:11AM 11:11AM 11:11AM 11:11AM 9 11:11AM

10 11:11AM 11 11:11AM

12 11:11AM 13 11:11AM

14 11:11AM

15 11:11AM

11:11AM 16

17 11:11AM

18 11:11AM

19 11:11AM

20 11:11AM

21 11:11AM

22 11:11AM

11:12AM 23

24 11:12AM

25 11:12AM

- Now, if we go to Page 33 of Exhibit 3, do you Q. 1 11:12AM see where it says the maximum beyond-use dates of 2 11:12AM compounded drugs? 3 11:12AM Yes. All the way on the bottom it says, "High 4 11:12AM risk level compounded sterile products." It says, "Not 5 more than 24 hours at room temperature, three days at 6 cold and 45 in solid frozen state." 7 11:12AM Now I'm going to show you what's previously 8 Q. 11:12AM been admitted as Plaintiff's Exhibit 6. Do you recognize this exhibit? 10 11:13AM Α. Yes, I do. 11 Q. And did you rely on this exhibit in forming 12 your opinion? 11:13AM 13
 - Yes, I did. Α.
 - I'm going to take you to -- do you see the date Q. that says 3-18-21?
 - 3-18-21, received from supplier line. Α. Yes, I see it.
 - According to these records, this is the last time that TDCJ received 50 milliliter vials of pentobarbital?
 - That's what it appears to be, from the records Α. that I was given.
 - So according to the USP, when would the 50 Q. milliliter vials of pentobarbital have expired?

- 11:12AM
- 11:12AM

- 11:12AM
- 11:13AM
- 11:13AM
- 14 11:13AM
- 15 11:13AM
- 16 11:13AM
- 17 11:13AM
- 18 11:13AM
- 19 11:13AM
- 20 11:13AM
- 21 11:13AM
- 22 11:13AM
- 11:13AM 23
- 24 11:13AM
- 25 11:13AM

So if this medication was stored in deep Α. 1 11:13AM freeze, that would be good for 45 days. So 3-18-21 -- I 2 11:13AM would say sometime early May of 2021 is when this 3 11:14AM medication would have expired. 4 11:14AM Q. I'm going to show you Plaintiff's Exhibit 7. 5 11:14AM Do you recognize this exhibit? 6 11:14AM 7 Α. Yes. 11:14AM And what is this exhibit? 8 Q. 11:14AM So this appears to be the storage inventory of 9 11:14AM the pentobarbital vials that have 100 milliliter volume. 10 11:14AM And do you see the entry that says 4-29-19? 11 Q. 11:14AM Yes. 12 Α. That's when I'm assuming the six vials 11:14AM were received, or six vials were -- let me see -- oh, 15 13 11:14AM vials were received from the supplier and added into the 14 11:14AM inventory. 15 11:14AM And according to these records, 4-29-19 is the Q. 16 11:14AM last time TDCJ received 100 milliliters vials of 17 11:14AM 18 pentobarbital? 11:14AM 19 Α. That's what it appears to be. 11:15AM According to USP, when would have the 100 20 Q. 11:15AM milliliter vials in TDCJ's possession have expired? 21 11:15AM Α. Sometime in mid June of 2019. 22 11:15AM

of pentobarbital in its possession?

11:15AM

11:15AM

11:15AM

23

24

25

Q.

Based on your review of the records, has TDCJ

been following the USP when extending the beyond-use date

1 11:15AM 2 11:15AM 3 11:15AM 4 11:15AM 5 11:15AM 11:15AM 6 7 11:15AM 8 11:16AM 9 11:16AM 10 11:16AM 11 11:16AM 12 11:16AM 13 11:16AM 14 11:16AM 15 11:16AM 16 11:16AM 17 11:16AM 18 11:16AM 19 11:16AM 20 11:16AM 21 11:16AM 22 11:16AM 11:17AM 23 24 11:17AM

25

11:17AM

A. No. Because what they appear to be doing is they just basically test the medication and if it appears that potency is there, then they somehow -- and I'm not really sure what the reasoning is -- they are just extending it beyond that. But you know, there are a lot of flaws in that particular methodology, number one being the fact that when you tested one vial from one batch, that is not representative of all of the other vials and all of the other batches that you have in possession.

So it's very important to have good quality manufacturing process like when you do 503B compounding or sterile compounding, you know, manufacturing where you have large batches and you have contact uniformity. When you are doing small scale, there's no guarantee that other vials are exactly the same. So that's one concern.

The other concern that I have is the fact that when you are testing the potency using an assay, the methodology that's used to test for the actual potency, the strength is not appropriate. You have to use a method that looks at the stability and looks at the degradation of the product, especially when these products are so old and expired.

Your stability indicating method will show you if there are any other potential degradants in the product itself. And those would be bundled in with the

11:17AM **1**11:17AM **2**

11:17AM 3

4

11:17AM 5

11:17AM

11:17AM 6
11:17AM 7

11:17AM 8

11:17AM 9

11:17AM 10

11:17AM **11**

11:17AM 12

11:17AM 13

11:17AM **14**

11:18AM 15

11:18AM **16**

11:18AM 17

11:18AM 18

11:18AM 19

11:18AM 20

11:18AM 21

11:18AM 22

11:18AM 23

11:18AM 24

11:18AM 25

main drug in an assay, so you would not be able to see them.

- Q. So in layman's terms, can you describe for the Court what TDCJ is doing to purportedly extend the B-U date of the pentobarbital in their possession?
- A. So from what I can tell from the records that are provided for my review, they basically test the drug and if it still has what they assume is the correct potency, which we are not really sure that it does, they just say all of the vials are still good, regardless whether they are 50 ml vials or 100 ml vials and they just somehow assign it the further date out.

But that's completely inappropriate, because what you need to do is you need to do a stability study that basically will determine what is the proper span for the medications expiring. So if you perform a stability study, then you will be able to project the dates forward. But you can't do that as you go; that's not a correct way of doing it. You can't just assume that next time we test it, it probably will be fine; it's fine between now and the next date.

- Q. And did they perform all the tests that are required under the United States Pharmacopeia?
- A. No. I also did not see all of the tests that they are supposed to do, and one that really concerns me

11:18AM 1
11:18AM 2
11:18AM 3
11:18AM 4
11:18AM 5
11:18AM 6
11:18AM 7

11:18AM 8
11:19AM 9
11:19AM 10
11:19AM 11
11:19AM 12
11:19AM 13

11:19AM

11:19AM

14

15

21

11:19AM 16
11:19AM 17
11:19AM 18
11:19AM 19
11:19AM 20

11:19AM 22 11:19AM 23

11:19AM

11:19AM 24

11:20AM **25**

is actually pH. PH is a concerning one because, number one, if the pH is not appropriate the drug may fall out of solution -- and you may say, "Oh, I don't see anything," because you may have microcrystal formation. There is actually potential for these difficult-to-see particles to be formed that you may not see with the naked eye.

And so they may -- so they really should perform pH to assess that the drug still has the pH that it's supposed to have. And of course, pH itself, if it's inappropriate, it can cause burning and pain at the injection site. So pH is definitely something that needs to be tested.

And also the sterility that they have performed or they had the contract lab to perform is done via scan RDI, which is a technology that provides quicker turnaround. It's a quick technology, but it is not as accurate. And in particular, it does not capture a lot of times some of the long-term microorganisms, some of the fungus, some of the microorganisms that you will only see in USP 71 methodology. So the sterility is not tested via correct method, either.

Q. I want to show you what is marked as Plaintiff's Exhibit 8. Do you recognize this exhibit?

A. Yes.

11:20AM	1	Q. Do you see it's from August 12, 2022?
11:20AM	2	A. Yes, that's correct.
11:20AM	3	Q. Can you see it's from TDCJ?
11:20AM	4	A. Yes.
11:20AM	5	Q. Do you see that on August 12, 2022, the
11:20AM	6	beyond-use date of the 2.5 gram vials in TDCJ's
11:20AM	7	possession was assigned at October 9, 2022, and
11:20AM	8	December 8, 2022?
11:20AM	9	A. Yes, that's correct.
11:20AM	10	Q. Do you see that on that same date the 5 gram
11:20AM	11	vials had beyond-use date or purported beyond-use date of
11:20AM	12	12-8-2022?
11:20AM	13	A. That's correct.
11:20AM	14	Q. Now I'm going to point you to Plaintiff's
11:20AM	15	Exhibit 9 which has already been admitted. Do you
11:20AM	16	recognize this exhibit?
11:20AM	17	A. Yes.
11:20AM	18	Q. Do you see it's an e-mail from TDCJ on
11:20AM	19	November 29, 2022?
11:20AM	20	A. Yes.
11:21AM	21	Q. Do you see that the beyond-use dates for
11:21AM	22	pentobarbital changed from that last e-mail?
11:21AM	23	A. Right.
11:21AM	24	Q. Can you tell the Court what those beyond-use
11:21AM	25	dates now are assigned by TDCJ?

11:21AM 1
11:21AM 2
11:21AM 3
11:21AM 4

11:21AM 5

11:21AM **7**

8

11:21AM 9

11:21AM

11:21AM 10

11:21AM 11

11:21AM 12

11:22AM 13

11:22AM 14

11:22AM 15

11:22AM 16

11:22AM 17

11:22AM 18

11:22AM 19

11:22AM 20

11:22AM **21**

11:22AM 22

11:22AM 23

11:22AM **24**

11:22AM 25

- A. They seem to be projected way out, far out. We are talking about September of 2023 and November of 2023. That's a really significant change from the previous beyond-use date.
- Q. Do you know how TDCJ extended the beyond-use dates of the pentobarbital in their possession?
- A. Unless they performed a stability study, I would say incorrectly, because there's no really other way of assigning beyond-use dates out far like this.

Like I said, we compound in my pharmacy, we compound medications according to 503B, according to CGMP regulations and we don't typically assign BUD's past 180 days. So it's really impressive they are able to extend the BUD this far out, but I would really wonder what type of documentation they have that they are able to do so.

- Q. Now I'm going to show you what's marked as Plaintiffs Exhibit 10 which has previously been admitted. Have you reviewed Plaintiff's Exhibit 10 before?
 - A. Yes.
- Q. Have you reviewed what testing has been done by the laboratory for TDCJ's pentobarbital?
- A. Yes, that's correct. This is an assay that was performed.
 - Q. What they have done, is that the proper way to

11:22AM **1**

2

11:22AM 3

11:22AM

11:22AM **4**

11:22AM 5

11:22AM 6

11:22AM **7**

11:22AM 8

11:22AM 9

11:23AM 10

11:23AM 11

11:23AM 12

11:23AM 13

11:23AM **14**

11:23AM 15

11:23AM 16

11:23AM 17

11:23AM 18

11:23AM 19

11:23AM 20

11:23AM 21

11:23AM 22

11:23AM 23

11:23AM **24**

11:23AM 25

extend the beyond-use dates of drugs according to the USP?

A. No. No, this is not the assay that you should use. This assay is traditionally used when you are performing quality control or maybe when you receive the raw material. So when you receive an API, active pharmaceutical ingredient, maybe from a manufacturer, you are going to do a compounding activity, you are going to receive the API and you will have it tested by a contract lab to make sure that it has the potency that you need.

So once you have that, then you are going to compound it and maybe at the end of your compounding procedure you will send out a sample to test it again. But this is all -- this assay is typically used to just verify that the drug has the potency that it has.

- Q. Based on the testing that you reviewed by the pharmacy or the laboratory, would it be appropriate to extend the beyond-use dates of the pentobarbital as far out as TDCJ has done?
- A. Using this methodology, no. You need to perform a stability indicating assay. And the stability indicating assay is the proper methodology that will explore how well is your drug holding up; are there any degradants that are potentially forming. And so you need to perform the stability indicating assay that will

11:23AM 1
11:24AM 2

11:24AM 3

11:24AM 5

11:24AM 6

11:24AM **7**

11:24AM 8

11:24AM

11:24AM 10

9

11:24AM **11**

11:24AM 12

11:24AM 13

11:25AM **14**

11:25AM 15

11:25AM 16

11:25AM 17

11:25AM 18

11:25AM 19

11:25AM 20

11:25AM **21**

11:25AM 22

11:25AM 23

11:25AM **24**

11:25AM **25**

analyze quality of a drug that, you know, you are looking at potentially extending the BUD for.

- Q. What I'm going to show you now, can you explain what this chart shows to the Court?
- A. Sure. So this is an example from just when you run your typical run-of-the-mill assay. So you want to know what is the potency of my medication, you want to know what is the -- how many milligrams of pentobarbital is in my solution, or any drug for that matter.

So what you will do is, this is a chromatography example from a HPLC, High Precision Liquid Chromatograph. It's a system that basically analyzing -- a very commonly used system in pharmaceutical industry and pharmacy in general.

So what happens is, you will analyze your medication. You will have a curve, so you are going to use for standards that will create a calibration curve so you can quantitate what -- you know, how much of the analyte you have. So you are going to create -- you purchase your USP standards from USP that basically you can confirm that it is the correct medication. And so you use the standards, you will make a calibration curve. And then you use this calibration curve to quantitate your recovery, to see that your drug that you compounded has the appropriate potency. So that's what this is.

11:25AM 1
11:25AM 2
11:25AM 3

11:25AM **5**

11:25AM

11:26AM

4

7

11:26AM 6

11:26AM **8**

11:26AM 9

11:26AM 10

11:26AM **11**

11:26AM 12

11:26AM 13

11:26AM **14**

11:26AM 15

11:26AM 16

11:26AM 17

11:26AM 18

11:26AM 19

11:26AM 20

11:26AM **21**

11:26AM 22

11:26AM 23

11:26AM **24**

11:26AM 25

So this is an example of your HPLC method that's used to analyze your finished product or maybe your API. You're just looking strictly for potency; you want to see how much of the drug is in a solution.

- Q. And this is the testing that TDCJ is doing to extend their beyond-use dates?
- A. I believe so, because it was listed at the bottom where they basically -- in the report, the analytical report, it said which methodology they used and they refer to USP; I think it's 624, which is an HPLC analysis. And of course, you will get more detail if you go into a nomograph for the pentobarbital. It will give you details of how to perform this analytical method.

But again, the monograph for the pentobarbital injection provides guidance on how to perform just a regular essay. So that's what this is. This is an example of an assay. You are just quantitating how much pentobarbital was in there and you are assuming that it's all just pure pentobarbital.

- Q. Can you describe for the Court what this picture shows?
- A. This is as great example of a stability indicating assay. So in this case what you are seeing is, it could be exactly the same sample that you the saw on the previous example. So it may be exactly same drug,

but if that drug is maybe close to expiring, maybe it's 1 expired, it's been around for a while, it has most likely 2 passed its expiry, you will start seeing degradants, 3 which is of course a natural process with any medication. 4 That's why we have expiration dates, because we can only 5 guarantee their quality and their activity up to the 6 expiry. And so once you start getting past the expiry, 7 you will start seeing degradants forming. 8

What you see in this example, you see the separation of the degradant from the analyte. So in the first example the degradant is basically part of the analyte because it's a different method. So this is a stability indicating method and your elution time in the mobile phase, the chemicals that basically help to kind of separate out your degradants are being used to basically see if there is any degradation.

So if you had a fresh drug, if you had pentobarbital that you just purchased from the manufacturer, you will not see the degradant at all. Or you may see a tiny little peak that would not really impact your total size of the analyte peak. But as the drugs degrade over time, you will start seeing these degradants and that's exactly what is shown here.

So you see this degradant that's a peak. I mean, in this case the peak is almost probably about

11:27AM 11:27AM 11:27AM 11:27AM 11:27AM 11:27AM 11:27AM 11:27AM 11:27AM 9 10 11:27AM 11 11:27AM 12 11:27AM 13 11:27AM 14 11:27AM 15 11:27AM 16 11:27AM 17 11:28AM 18 11:28AM 19 11:28AM 20 11:28AM 21 11:28AM 22 11:28AM 11:28AM 23

24

25

11:28AM

11:28AM

11:28AM 1
11:28AM 2
11:28AM 3
11:28AM 4
11:28AM 5

11:28AM **7**

11:28AM

11:28AM

6

8

11:29AM 9
11:29AM 10
11:29AM 11

11:29AM 12 11:29AM 13

11:29AM 14

11:29AM **16**

11:29AM 10

11:29AM **17**

11:29AM 18

11:29AM 19

11:29AM 20

11:29AM **21**

11:29AM **22**

11:29AM 23

11:29AM 24

11:29AM 25

80 percent the size of the analyte peak. So this would be completely different and this could be a different chemical and most likely is a very different structure that might not have any of the pharmacologic activity of your analyte.

Q. So can you describe in layman's terms for the Court what a degradant is?

A. So a degradant is basically a chemical entity that just develops from whatever you have, let's say a pentobarbital molecule. Over time it just -- it gets exposed to light, maybe a different temperature, and so it kind of falls apart and the structures change.

So eventually these other chemicals that are being formed from the mother analyte, from the original peak, these other peaks that are being formed, these are different chemicals. At times -- I was looking at some literature to see the degradation process of pentobarbital and I do believe I included it in my expert report as well. There is an example of degradation of pentobarbital.

But what happens, the pentobarbital actually breaks down into some of the entities that initially when you are preparing pentobarbital from raw materials -- so those chemicals that you made it from -- those are the chemicals that it basically goes back to.

So it kind of falls apart into those.

- Q. So is pentobarbital known to have degradants that form over time?
- A. Yes. Yes, of course. Yes, a majority of the medications do.
- Q. And when those degradants form over time, do they have the same pharmacological effect as pentobarbital itself?
- A. No, they do not. A lot of times they are not studied just because, you know, there is really -- we don't use medications that are past expiry, so we typically don't study them in great detail.

But I was curious and I looked up a couple because, like I said, those are actually, for pentobarbital, those are actually drugs that they started with. I shouldn't say drugs; they are chemicals that they started with and then they synthesized the pentobarbital.

So some of them do have some described activity and, if I remember correctly, one of them was stimulating the pancreas. Like they do not have any more pharmacological activity of the pentobarbital; they are very different structures.

Q. And the potency testing that was done by the pharmacy employed by TDCJ, did they do testing to detect

- 1 11:29AM 2 11:30AM 3 11:30AM 4 11:30AM 5 11:30AM 6 11:30AM 7 11:30AM 8 11:30AM 11:30AM 10 11:30AM 11 11:30AM 12 11:30AM 13 11:30AM 11:30AM
- 11:30AM 13
 11:30AM 14
 11:30AM 15
 11:30AM 16
 11:30AM 17
- 11:30AM 18

11:30AM

19

- 11:30AM 20
- 11:30AM 21
- 11:30AM 22
- 11:30AM 23
- 11:30AM 24
- 11:31AM 25

11:31AM 1 the degradants?

A. I don't believe so because they use the standard assay method, and the assay method is not a stability indicating method. So it's a different method. So when they run the assay, they will just see one peak. That peak could actually be containing all of these other degradants, but you don't see them because you are using different methods. So you are not eluting, you are not separating out all of the degradants; instead you are just running it as a one-peak. So it will appear as a one-peak and in reality it could be serial peaks that you are just not seeing.

Q. Now I'm going to show you again Plaintiff's Exhibit 7. If I take you to Page 3 of Plaintiff's Exhibit 7, can you tell the Court the last time TDCJ returned a vial to the lab to test the 100 milliliters vials of pentobarbital?

A. So it appears on here it was all the way on the bottom. December 20, 2021, return to supplier or -- yes, I think so.

- Q. If you look at Page 4, which is the very last page, were there any times after December 20, 2021, that TDCJ returned one of the 100 milliliter vials to the laboratory to be tested?
 - A. No, there does not appear to be.

11:31AM 2 3 11:31AM 4 11:31AM 5 11:31AM 11:31AM 6 7 11:31AM 8 11:31AM 9 11:31AM 10 11:31AM 11 11:31AM 12 11:31AM

11:31AM 13
11:31AM 14
11:31AM 15
11:32AM 16

11:32AM 17

11:32AM **19**

11:32AM 20

11:32AM **21**

11:32AM **22**

11:32AM 23

11:32AM **24**

11:32AM **25**

11:32AM	3
11:33AM	4
11:33AM	5
11:33AM	6
11:33AM	7
11:33AM	8
11:33AM	9
11:33AM	10
11:33AM	11
11:33AM	12
11:33AM	13
11:33AM	14
11:33AM	15
11:33AM	16
11:34AM	17
11:34AM	18
11:34AM	19
11:34AM	20
11:34AM	21
11:34AM	22
11:34AM	23
11:34AM	24
11:34AM	25

1

2

11:32AM

11:32AM

- Q. Now let's turn to Exhibit 6 which is already been admitted. And if I take you to Page 2, can you tell the Court the last time TDCJ returned a 50 milliliter vial to the supplier to be tested?
- A. It appears it is September 30, 2022. That's what it says, "Return to supplier."
- Q. Do you also see, I believe it says 9-30-2022, as well, "Return to supplier"?
- A. Yes, 9-30-2022, "Return to supplier." That's correct.
- Q. And that would have been between the two e-mails that I showed you before, correct; the e-mail on August 12, 2022, and the e-mail on 11-29-22 from TDCJ?
 - A. Yes, that's correct.
- Q. So from August 12, 2022 when TDCJ sent that first e-mail to 11-29-2022, were any of the 100 milliliter vials returned to the supplier?
 - A. I don't believe so.
- Q. If none of those vials were returned to the supplier, could there be a scientific basis to extend the BUD of the 100 milliliter vials?
- A. No, absolutely not, because that's a couple of different sizes, a potentially different container, container closure. So all that, it's not just the drug itself, but you know you have a potential different

compounding process. You definitely have a different 1 11:34AM container size and volume. All of that would require its 2 own testing to be able to project -- or not even project, 3 but to test the assay to figure out what is the potency. 4

- Q. But even though in your expert opinion there was no scientific basis based on your review of the records, you saw that TDCJ nevertheless extended the BUD of the 100 milliliter or 5 gram vials of pentobarbital?
- They did, but I am not really sure how they Α. could have done that with what they are supposed to be doing. They did not follow the proper procedures.
- Now let's talk about the 50 milliliter vials. Q. You just testified a minute ago that TDCJ transferred 102 vials during the period of the two e-mails, right?
 - Yes. Α.
- In terms of extending the BUD for all 50 Q. milliliter vials, even if they did the correct testing on those two vials, would it be consistent after correct testing on two vials to extend the entire batch of the 50 milliliter vials?
- No, because they are not representative. Also I'm concerned, I'll be honest, that does not seem to be -- of course there's a redacted portion, so maybe that's what data is hiding. But it does not appear that there is a very good control, inventory control in terms of lot

11:34AM 11:34AM 11:34AM 5 11:34AM

11:34AM 6 7 11:34AM

11:34AM

11:35AM

8

9

10 11:35AM

11 11:35AM

12 11:35AM

13 11:35AM

14 11:35AM

15 11:35AM

16 11:35AM

17 11:35AM

18 11:35AM

19 11:35AM

20 11:35AM

21 11:35AM

22 11:35AM

11:36AM 23

24 11:36AM

25 11:36AM

numbers. 1 11:36AM

2

3

8

And so it would be very crucial to test, if you have any testing performed, that it really relates to vials you tested. It does not relate to different batches and different products, different sizes or anything like that; those are just the ones that you tested.

- Now based on your review of the records, did Q. TDCJ test the pH of the pentobarbital?
 - No, it was not included in the report.
- Is that required to extend the BUD under the Q. USP?
- Absolutely, yes, all of the testing that's Α. listed in the monograph -- so when you have a pentobarbital injection monograph that's listed in the USP compounding, it lists all that needs to be performed, and pH is one of them. So whenever you perform any kind of stability studies, you will make sure that your stability study results will meet all of the USP monograph requirements.
- Based upon your review of the records, was Q. visual inspection performed to extend the BUD of the pentobarbital?
 - Α. It was not recorded on the report.
 - Is this required by USP? Q.

4 11:36AM 5 11:36AM 11:36AM 6 7 11:36AM

11:36AM

11:36AM

9 11:36AM 10

11:36AM

11:36AM

11 11:36AM

12 11:36AM

11:36AM 13

14 11:36AM

15 11:36AM

16 11:36AM

17 11:36AM

18 11:36AM

19 11:37AM

20 11:37AM

21 11:37AM

22 11:37AM

23 11:37AM

24 11:37AM

25 11:37AM

11:37AM **1**

11:37AM 2

11:37AM **3**

11:37AM

4

5

7

8

9

11:37AM

11:37AM 6

11:37AM

11:37AM

11:37AM

11:37AM 10

11:37AM 11

11:37AM 12

11:37AM 13

11:37AM **14**

11:38AM 15

11:38AM **16**

11:38AM 17

11:38AM 18

11:38AM 19

11:38AM 20

11:38AM 21

11:38AM 22

11:38AM 23

11:38AM 24

11:38AM 25

- A. Yes, it is.
- Q. Can you tell the Court why visual inspection is important?
- A. Visual inspection is very important in particular with injectable drugs because you need to examine it in case there is any formation of precipitation.
- Q. Dr. Almgren, we discussed this a bit before, but did TDCJ test at all for sterility?
- A. Yes, it did appear that they did test the sterility of the products.
 - Q. Was it the correct test for sterility?
- A. No, it was not correct. They were using scan RDI instead of the required method in USP 71 that is specified in a monograph for pentobarbital injection.
- Q. Now, let's talk about TDCJ's record keeping in relation to the pentobarbital. Can you describe for the Court how drugs are removed from storage when they are tested?
 - A. In the case of TDCJ or just the regular how?
- Q. In TDCJ; meaning does it just show that they are re-sent to the supplier?
- A. Yes, that's what appears. So they basically take them out of the inventory, then it appears it says, "Return to supplier." What's really not good is the fact

11:38AM 1
11:38AM 2
11:38AM 3
11:38AM 4
11:39AM 5
11:39AM 6

11:39AM 7 11:39AM 8

11:39AM 10

11:39AM

9

13

11:39AM 11 11:39AM 12

11:39AM **14**

11:39AM

11:40AM 15
11:40AM 16

11:40AM 17

11:40AM 19

11:40AM **21**

11:40AM 22

11:40AM 23

11:40AM 24

11:40AM 25

that they don't have really any storage details about the temperature, how the drugs are actually stored. And then when they are transferred, if they are being shipped to the supplier, are they in frozen state, are they in a refrigerator? None of that is documented and it just says, "Return to supplier."

- Q. Now I'm going to show you again Exhibit 7. We're going to go to Page 3. Do you see on 9-8-20 they returned a vial to the supplier?
 - A. Yes, I do see that.
- Q. Then if you go to Exhibit 10 which has already been admitted, I'm going to take you to Page 3. Do you see on 9-18-2020 they tested a vial?
 - A. Yes, that's correct.
- Q. Now if we go back to Exhibit 7 that you just saw before, do you see on 1-21-21 a vial was returned?
- A. Yes. I saw that, yes. The assumption I'm making is that a vial was sent out to the supplier who then sent it off to be tested. The drug was tested and then it was returned back and put back into inventory, which is completely inappropriate. You cannot return medication after it was tested back into inventory by -- you would never, you should never use it in a patient, never use it in a person because the medication could be tampered with.

It was not stored properly, it was opened, 1 a portion of it was removed for testing. There's a verv 2 good potential for bacterial contamination or, for that 3 matter, physical or chemical contamination, as well. 4 vials like that should never be returned; that should 5 have been disposed of. 6 7 Q. And is that practice consistent with the USP,

- to test a vial and then return it?
- No, you would never do that. It's not Α. consistent with the USP, FDA, pharmacy general practice, you know, aseptic technique. All of those would direct you to not use vials that have been opened and tested.
- Now let me direct your attention again to Q. Exhibit 7. You see it says "Expired"?
 - Α. Yes.
 - And one vial was taken out of storage? Q.
 - Yes. Α.
- Q. What does that tell you as an expert in pharmacy?
- It's actually extremely mind boggling, I'll be honest with you, because I don't understand how you can have one vial that's expired. How did you identify that this vial expired, how were you able to determine by looking at it that it's expired and why were there not other vials within the same batch that were also expired.

11:40AM 11:40AM 11:40AM 11:41AM 11:41AM 11:41AM 11:41AM 11:41AM 11:41AM 11:41AM

10 11 11:41AM 12 11:41AM 13 11:41AM

8

9

14 11:41AM

15 11:41AM

11:41AM 16

17 11:41AM

18 11:41AM

19 11:41AM

20 11:41AM

21 11:41AM

22 11:42AM

11:42AM 23

24 11:42AM

25 11:42AM

1 11:42AM 2 11:42AM 3 11:42AM 4 11:42AM 5 11:42AM 11:42AM 6 7 11:42AM 8 11:42AM

11:42AM 10 11:42AM 11

11:42AM

11:42AM

11:42AM

11:43AM

9

12

14

17

11:42AM 13

11:42AM **15**

11:43AM 16

11:43AM 18

11:43AM **19**

11:43AM 20

11:43AM **21**

11:43AM 22

11:43AM 23

11:43AM **24**

11:43AM 25

I think it's very poor practice and there should be, if nothing else, some form of explanation of why this vial was expired. But that's very disturbing because it just tells me that the folks who are handling these medications, my assumption is they probably looked at a vial and maybe saw some physical changes that made them expire this. But you never just expire one vial.

If one vial has -- you see some type of changes, you're going to expire all within the same lot. Because there's a very good chance that all of them are going through the same chemical changes or physical changes as this one; you may just not be able to quite see them, but they may definitely be happening.

- Q. In your career as a pharmacist has there ever been a situation where you had one vial expired but the rest of the batch was not?
- A. No, no. We would not do that. I mean, if one expires, all expire.
- Q. Dr. Almgren, based on the documents you have reviewed and on your professional experience, what is your scientific opinion about the pentobarbital in TDCJ's possession?
- A. It is expired. It is well beyond the beyond-use date, and there's really no way to tell what state the medication is in, if it's, you know -- how much

11:43AM	1	of it is actually still pentobarbital, how much of it is
11:43AM	2	degradants. It's difficult to tell because it has not
11:43AM	3	been analyzed using a stability method.
11:43AM	4	Q. Do you hold this opinion to a reasonable degree
11:43AM	5	of scientific certainty?
11:43AM	6	A. I do.
11:43AM	7	MR. KURSMAN: I have nothing further, Your
11:43AM	8	Honor.
11:43AM	9	THE COURT: Could you go ahead and unshare
11:44AM	10	your screen. I need to give Ms. Hayes a break. And I'm
11:44AM	11	cognizant of the doctor's time before we do that, so I
11:44AM	12	need to take at least a 10-minute break because my court
11:44AM	13	reporter can't keep going.
11:44AM	14	Let me ask counsel for Mr. Brown, do you
11:44AM	15	have questions for this witness or are we going to go
11:44AM	16	directly to the State?
11:44AM	17	MR. SCHARDL: Nothing from Mr. Fratta, Your
11:44AM	18	Honor.
11:44AM	19	MR. WOLFF: Nothing for Mr. Brown. Thank
11:44AM	20	you, Your Honor.
11:44AM	21	THE COURT: Thank you. Let's be on break
11:44AM	22	for ten minutes.
11:44AM	23	(Whereupon There was a Break in the Proceedings)
11:57AM	24	THE COURT: All right, Ms. O'Leary.
11:57AM	25	MS. O'LEARY: Yes, Your Honor.

CROSS-EXAMINATION 1 11:57AM BY MS. O'LEARY: 2 11:57AM Good morning, Dr. Almgren. I just have a few 3 Ο. 11:57AM questions and I'll try to make it quick because I know 4 11:57AM you are on a quick turnaround. 5 11:57AM You have not worked in a pharmacy where you 11:57AM 6 7 compounded lethal doses of a drug; is that accurate? 11:57AM That's correct. Α. 8 11:57AM You testified earlier that it is really Q. 11:57AM difficult to assess what the pharmacological activity 10 11:57AM might be in TDCJ's supply of drugs; is that accurate? 11 11:57AM 12 Α. Right. 11:57AM Are you familiar with a study conducted by a Q. 13 11:57AM Priest Geisbuhler where he [sic] studied injectable 14 11:57AM sodium pentobarbital stability at room temperature? 15 11:57AM I am, and actually I read it last night just to Α. 16 11:57AM make sure that I'm up-to-date on all of the literature, 17 11:58AM 18 so yes. 11:58AM 19 Q. Okay good. So let me get to the table here. 11:58AM THE COURT: Hold on one second. I'm sorry. 20 11:58AM I should have asked Ms. Hayes -- I need to make sure 21 11:58AM Ms. Hayes is with us. 22 11:58AM THE STENOGRAPHER: Yes, I'm here. 11:58AM 23 Thank you. Proceed. THE COURT: Ok. 24 11:58AM MS. 0'LEARY:

25

11:58AM

Thank you, Your Honor.

1 11:58AM 2 11:58AM 3 11:58AM 4 11:58AM 5 11:58AM 6 11:58AM 7 11:58AM 8 11:58AM 11:58AM 10 11:58AM 11 11:59AM 12 11:59AM 11:59AM 13 14 11:59AM 15 11:59AM 16 11:59AM 17 11:59AM 18 11:59AM 19 11:59AM 20 11:59AM 21 11:59AM 22 11:59AM 23 11:59AM 24 11:59AM

25

11:59AM

- Q. (Ms. O'Leary) In that study the person who conducted the study says that about 15 to 25 milligrams of pentobarbital is a lethal does. Is that consistent with your understanding of pentobarbital?
 - A. I guess so.
- Q. You are not familiar with what would be a lethal does of pentobarbital?
- A. No, no. I mean yeah -- yeah, I mean pentobarbital is a very potent drug.
- Q. Okay. And so if 15 to 25 milligrams is a lethal does, are you aware that TDCJ uses about 10 times that to conduct lethal injection?
- A. Right. I'm assuming you use a whole 50? What do you normally use? Is it a vial?
- Q. So it's five grams and five more grams as a backup.
 - A. Right.
- Q. In that same study the lab conducted studies of compounded pentobarbital solution, which is similar to what we're discussing today. Did you see the part where he -- his finding is that the chemical degradation occurs at about half a percent per year for sodium pentobarbital compound?
- A. So I would like to point out one thing, and I'm not sure that we can share the document in any way

Ιf

because it appears like maybe you have it on paper. 1 11:59AM If you read that study, if you will start 2 12:00PM -- I think it's on maybe, it's on the first page. 3 12:00PM study starts off by discussing the two methods that they 4 12:00PM have used. Can you -- I wish -- can I look? I have that 5 12:00PM study on my computer. Would it be okay for me to open it 12:00PM 6 so we can talk about the same study together? I have the 7 12:00PM study right here. 8 12:00PM Well, let me just re-ask the question. 12:00PM 9 No, ma'am. THE COURT: Doctor, just let 10 12:00PM Ms. O'Leary ask her question, please. 11 12:00PM 12 Q. (Ms. O'Leary) Do you agree that that finding 12:00PM concludes that it degrades at half a percent per year? 13 12:00PM No, they use incorrect method. So there are 14 12:00PM two methods --15 12:00PM That's not my question. Q. I'm sorry. 16 12:00PM MR. KURSMAN: Objection, Your Honor. 17 12:00PM Ms. O'Leary is going to ask these questions, I would just 18 12:00PM 19 ask that she allow Dr. Almgren to answer those questions. 12:00PM THE COURT: Well, I think Dr. Almgren, she 20 12:00PM did answer it. She said no, she did not agree. 21 12:00PM Ms. O'Leary can ask her next question. 22 12:00PM

12:01PM

12:01PM

12:01PM

23

24

25

Q.

Is that what you mean?

(Ms. O'Leary) Your explanation, Doctor, is

that was the finding, but you disagree with the methods.

1 12:01PM 12:01PM 2 3 12:01PM 4 12:01PM 5 12:01PM 12:01PM 6 7 12:01PM 8 12:01PM 12:01PM 9

12:01PM 10
12:01PM 11
12:01PM 12
12:01PM 13
12:01PM 14
12:01PM 15

12:02PM 17
12:02PM 18
12:02PM 19
12:02PM 20
12:02PM 21

12:02PM

16

22

23

12:02PM **24**

12:02PM

12:02PM

12:02PM **25**

A. That's exactly what I mean. When you read the article, they quote two separate methods. So they have a method by Morley and Elrod and they have a method by is it Reef? There are two different methods. So the method that they use is the one by Morley and Elrod, and that method is actually your analytical method that you use for confirmation of analyte.

The second method that is used by, like I said, I think it's Reef and --- I can't remember; there are a couple of other authors on the other method. That is the stability indicating method. And they did not use that one, so they don't explain in that particular study based on what they chose, the Method One. But they just performed Method One, which is not stability indicating; it does provide the guidance on how to perform an assay.

So that's why I disagree with them being able to assess the degradation being 0.5 percent per year. Because if you are not using correct method, what they are really just showing is that, using the regular analytical method, they are seeing some degradation as well. I think an actual stability indicating method would probably show a higher percentage of degradation.

Q. So that first method, is that the method that TDCJ uses in their testing that you also disagree with, the standard assay?

1 12:02PM 12:02PM 2 3 12:02PM 4 12:02PM 5 12:02PM 12:02PM 6 7 12:02PM 8 12:02PM 12:02PM 9 10 12:03PM 11 12:03PM

12:03PM 12
12:03PM 13
12:03PM 14
12:03PM 15
12:03PM 16

12:03PM 17

12:03PM **19**

12:03PM **20**

12:03PM **21**

12:03PM **22**

12:03PM **23**

12:03PM **24**

12:03PM **25**

- A. So I would have to look, honestly, because I do not know 100 percent. It sounds like the method that's used, but I could not confirm it without actually seeing chromatography and seeing the settings what buffer they use, elution method. There are a lot of details that would have to be confirmed.
 - Q. Okay. That's fine if you are not sure.

So one last question about this study, the finding was that the pentobarbital solution had a -- let's see what the terminology is -- it was good for as long as six years. And my question for you is, do you agree that that was the finding even if you don't -- if you disagree with the method, that's fine; you have already said that -- but that was the finding of this particular study; is that right?

A. That study is incorrect. You know, if you read through that study --

MS. O'LEARY: I'll object to nonresponsive, Your Honor.

THE COURT: Sustained. Doctor, just listen to her questions and answer her specific questions, please.

- A. Can you restate the question again? I'm sorry.
- Q. I believe you gave the answer. You disagree with the methods but the finding was, in fact, that it

12:03PM	1	was good for six years?
12:03PM	2	A. No, it's not.
12:03PM	3	Q. Okay.
12:03PM	4	A. Can I comment why I think it's not correct?
		·
12:03PM	5	THE COURT: Not at this point, ma'am. You
12:03PM	6	may have a chance when we go on, but not now.
12:04PM	7	MS. O'LEARY: I pass the witness, Your
12:04PM	8	Honor.
12:04PM	9	THE COURT: Mr. Kursman, do you have any
12:04PM	10	follow-up?
12:04PM	11	MR. KURSMAN: Just very briefly.
12:04PM	12	REDIRECT EXAMINATION
12:04PM	13	BY MR. KURSMAN:
12:04PM	14	Q. Dr. Almgren, can you tell the Court why that's
12:04PM	15	not correct?
12:04PM	16	A. Yes. It is incorrect because if you are using
12:04PM	17	incorrect method, analytical method, you are not going to
12:04PM	18	be able to assess stability. So that's my number one
12:04PM	19	comment.
12:04PM	20	Number two concern is, if you read that
12:04PM	21	study, it also talks about how the authors were unable to
12:04PM	22	explain why they were not seeing changes, greater changes
12:04PM	23	in potency when they were seeing changes in color. And
12:04PM	24	typically change in color is a major concern and, as a
12:04PM	25	matter of fact, per USP you would not be able to use a

drug that changed color, as in you need to -- the color 1 12:04PM of the drug indicates that there are some changes 12:04PM 2 happening. 3 12:04PM And so the fact that they noted and they 4 12:04PM did measurements trying to capture the change in color 5 12:04PM over time, the fact that they noted they saw changes but 12:04PM 6 they were not able to explain how come the potency didn't 12:04PM 7 change is just a true indication that study was not done 8 12:05PM correctly. 12:05PM 9 I also want to point out one more thing. 10 12:05PM They really were not looking at USP standards and this 11 12:05PM 12 drug being used in humans. This study was strictly 12:05PM focused on the fact that this drug was used for animal 13 12:05PM studies. And so I think that they were trying to kind of 14 12:05PM justify why they are using this drug past expiry and 15 12:05PM making sure it is potent enough for animals. So I think 16 12:05PM that that was their -- the intent was not here to extend 17 12:05PM 18 beyond-use date for human use. 12:05PM I have nothing further, Your 19 MR. KURSMAN: 12:05PM Honor. 20 12:05PM 21 THE COURT: Ms. O'Leary, do you have 12:05PM

Sorry, Your Honor. I have no

May this witness be excused?

MS. O'LEARY:

further questions for this witness.

THE COURT:

anything further?

22

23

24

25

12:05PM

12:05PM

12:05PM

12:05PM

12:05PM	1	MR. KURSMAN: Yes, Your Honor.
12:05PM	2	THE COURT: All right. Thank you, Doctor.
12:05PM	3	I hope we can get you to your class on time. Thank you
12:05PM	4	for your time and your testimony. You may be excused,
12:06PM	5	which means you may log off of Zoom, if you'd like.
12:06PM	6	Mr. Kursman, do you want to respond, now
12:06PM	7	that we've gotten the doctor's testimony, to the legal
12:06PM	8	points Ms. O'Leary made previously or do you have any
12:06PM	9	other evidence you would like to present first?
12:06PM	10	MR. KURSMAN: Yeah, I do, Your Honor.
12:06PM	11	Could I turn to Ms. Nelson-Major who will respond to the
12:06PM	12	statutory arguments made?
12:06PM	13	THE COURT: Yes. That's fine.
12:06PM	14	Ms. Nelson-Major.
12:06PM	15	MS. NELSON-MAJOR: Good afternoon, Your
12:06PM	16	Honor. I would like to begin by responding to the
12:06PM	17	argument that Ms. O'Leary made in her opening statement
12:06PM	18	that <u>Blaze vs. Rees</u> provides applicable legal standard
12:06PM	19	here in that the temporary injunction should not issue
12:06PM	20	because we have not proffered an alternative to the use
12:06PM	21	of expired pentobarbital.
12:06PM	22	This is not an 8th Amendment challenge.
12:06PM	23	Petitioners are not challenging the protocol and they are
12:06PM	24	not challenging the use of compounded pentobarbital in
12:06PM	25	general. No prisoner in Texas has brought a similar

1 12:07PM 12:07PM 2

3

5

9

11

4 12:07PM

12:07PM

12:07PM

12:07PM 6

7 12:07PM

8 12:07PM

12:07PM

12:07PM

10 12:07PM

12

12:07PM

13 12:07PM

14 12:07PM

15 12:07PM

16 12:07PM

17 12:07PM

18 12:07PM

19 12:07PM

20 12:07PM

21 12:08PM

22 12:08PM

23 12:08PM

24 12:08PM

25 12:08PM

challenge before under the four state statutes that are at issue in this complaint; so therefore, the 8th Amendment standards are completely irrelevant and not before this Court.

I would next like to turn to the arguments that Respondents have made about the various state statutes at issue here. I would like to go through each statute individually, but I would like to first note that one overarching theme runs throughout all of the arguments that Respondents have made. essentially that they are above the law and that when carrying out executions state statutes do not apply to their conduct. They urge that as long as lethal injection is the method used, but no ultra vires claims can lie with respect to the drugs or how they are administered.

If this argument is accepted, essentially it would mean that Respondents are immune, automatically immune from any state statute or constitutional restraints from carrying out an execution. Discretion is bound by the law, no matter how much power Respondents wish to afford themselves. And when carrying out official duties state actors must comply with statutory That's the entire point of the ultra vires framework. doctrine. And I would argue that compliance with the law

1 12:08PM 12:08PM 2

3 12:08PM

4 12:08PM

5 12:08PM

12:08PM 6

7 12:08PM

8 12:08PM

12:08PM 9

10 12:08PM

11 12:08PM

12 12:08PM

12:09PM

13

14

12:09PM

15 12:09PM

16 12:09PM

17 12:09PM

18 12:09PM

19 12:09PM

20 12:09PM

21 12:09PM

22 12:09PM

12:09PM 23

24 12:09PM

25 12:09PM

is of paramount importance when the State is doing something so serious and final as taking a life.

I would like to turn to the Texas Pharmacy Act. Ms. O'Leary suggested that the Texas Pharmacy Act does not apply because it only applies in the context of treating patients for treatment. In support of this argument they rely on one of the two stated legislative purposes that are found in the Texas Pharmacy Act, and those appear at Texas Occupational Code Section 551.002(c).

In making this argument they completely ignore the other stated legislative purpose of the Texas Pharmacy Act, and that is to regulate and control the practice of pharmacy. Respondents have elected to use a method of execution that relies on the practice of pharmacy. As such, application of the Texas Pharmacy Act, the lethal injection context is completely consistent with the legislative purpose of the act.

Furthermore, there's a statement that appears along with the legislative purposes which states that the act was enacted to ensure that the practice of pharmacy receive the confidence of the public. Here that goal is also of paramount importance. The public must be confident that the drugs used to carry out executions are compounded in a professional way and will not cause pain

1 and suffering.

Respondents cite a number of Administrative Code provisions to further argue that the Pharmacy Act does not apply here. They cite language which unfortunately only applies to nonsterile compounding, and thus Dr. Almgren explained the pentobarbital in TDCJ's possession applies to sterile compounded preparations, so those provisions are also irrelevant.

And I want to specifically address the regulation at the heart of claim one of Petitioners' complaint, and that appears at Administrative Code Section 291.133(b)(9). That's the regulation which prohibits the administration of an expired drug. The only drug that a pharmacist is authorized to administer is Epinephrine. So therefore, Respondents' argument that this provision only applies to pharmacists is clearly inconsistent with the plain language of the statute. It's obviously intended to reach conduct by individuals other than pharmacists.

And I would also like to note that the pharmacist that actually prepares the drugs for TDC is also named as a respondent in this action, and is the proper respondent in this action as well.

So for those reasons the arguments that Respondents have made about the applicability of the

25

12:11PM

1 12:11PM 12:11PM 2 3

5

9

4 12:11PM

12:11PM

12:11PM

12:11PM 6

7 12:11PM

8 12:11PM

12:11PM

12:11PM

10 12:11PM

11

12 12:12PM

13 12:12PM

14 12:12PM

15 12:12PM

16 12:12PM

17 12:12PM

18 12:12PM

19 12:12PM

20 12:12PM

21 12:12PM

22 12:12PM

12:12PM 23

24 12:12PM

25 12:12PM

Texas Pharmacy Act are inaccurate and inconsistent with the plain language, as well as the legislative purpose of the Texas Pharmacy Act.

I would like to move on to the Controlled Substances Act unless Your Honor has questions about the applicability of the Pharmacy Act.

> THE COURT: No. Go ahead.

MS. NELSON-MAJOR: Respondents argue that they are immune from the Controlled Substances Act because they are carrying out an execution. broad exception they cite Health and Safety Code Section 481.062(a)(4) and argue that they need not comply with the Controlled Substances Act. However, that subsection provides that a state actor may possess a controlled substance if they are lawfully engaged in the enforcement, and I quote, "of a law relating to a controlled substance or drug or to a customs law."

Respondents urge that they fall under this provision simply because they are carrying out an However, they are asking this Court to execution. completely disregard the explicit limitation in this provision which says that state actors may possess controlled substances when enforcing only two kinds of The Controlled Substance Act or a customs law. laws: When Respondents carry out executions, they are clearly

12:12PM **1**

12:12PM **2**

12:12PM **3**

12:12PM **4**

12:13PM 5

12:13PM 6

12:13PM **7**

12:13PM 8

12:13PM 9

12:13PM 10

12:13PM 11

12:13PM **12**

12:13PM 13

12:13PM **14**

12:13PM 15

12:13PM **16**

12:13PM 17

12:13PM 18

12:14PM 19

12:14PM **20**

12:14PM **21**

12:14PM 22

12:14PM 23

12:14PM **24**

12:14PM 25

doing neither; therefore, this exemption does not cover their conduct.

Alternatively, Respondents argue that they are immune from the CSA because they possess a DEA license. Again, they are asking the Court to rewrite the play language of this exception. That exception they cite appears at Section 481.061 of the Controlled Substances Act. They seem to argue that this provision means that anyone with a DEA license is automatically immune and exempt from compliance with the CSA. This is absolutely not true. The provision they cite says that a person with a DEA license may "possess, manufacture, distribute, analyze, dispense or conduct research with a substance to extent authorized by the chapter and in conformity with the chapter."

I first note that this provision doesn't speak of administration of the controlled substance. Petitioner's CSA claim is related to the administration of a controlled substance; so therefore, the provision doesn't even reach the conduct at issue. But furthermore, the statute is clear that, even if you possess a DEA license, your conduct with respect to the covered activities must still be in conformance with the statute.

I would also note that Respondents haven't

12:14PM **2**

12:14PM

1

12:14PM 3

12:14PM **4**

12:14PM **5**

12:14PM 6

12:14PM **7**

12:14PM 8

12:14PM 9

12:14PM 10

12:15PM **11**

12:15PM **12**

12:15PM 13

12:15PM **14**

12:15PM 15

12:15PM 16

12:15PM 17

12:15PM 18

12:15PM 19

12:15PM **20**

12:15PM **21**

12:15PM **22**

12:15PM 23

12:15PM **24**

12:15PM **25**

offered any evidence to demonstrate that they have a valid DEA license. We have received several DEA forms in response to Public Information Act requests. We don't have any information about the actual DEA license they claim to possess and whether that encompasses schedule II controlled substances which pentobarbital, in fact, is.

And in addition to those two arguments I would also note that the Controlled Substance Act has an explicit exception for humane society and animal control personnel to possess pentobarbital for the use in euthanizing animals, and that appears at Health and Safety Code Section 481.11(b). And no similar exception exists that would authorize Respondents to possess pentobarbital without a prescription for use in executions. So therefore, the arguments that Respondents made that they are immune and above the Controlled Substance Act fail and are inconsistent with the plain language of that statute.

Similarly, the arguments they made with respect to the Food, Drug and Cosmetic Act similarly find no basis in the plain language of the statute. They argue that they are immune and above the FDCA because they are not introducing drugs into commerce; however, they cite no statutory provision that supports this reading and the prescription requirement in the FDCA

12:16PM **1**12:16PM **2**

12:16PM **3**

12:16PM **4**

12:16PM **5**

12:16PM **6**

12:16PM **7**

12:16PM 8

12:16PM 9

12:16PM 10

12:16PM **11**

12:16PM **12**

12:16PM 13

12:16PM **14**

12:16PM 15

12:16PM **16**

12.10111 10

12:16PM

17

12:16PM 18

12:17PM 19

12:17PM 20

12:17PM **21**

12:17PM 22

12:17PM 23

12:17PM 24

12:17PM 25

contains no such language. Again, Respondents are asking this Court to rewrite the statutes and create exceptions for their conduct that simply do not exist.

And lastly with respect to the Texas Penal Code, Respondents argue that they are exempt from this statute as well because they are carrying out executions. Respondents have cited no legal authority for this argument whatsoever. Perhaps sensing that that argument is without any statutory foundation, they argue that their conduct is nonetheless justified because they reasonably believe that they were not subject to the Texas Penal Code. However, that belief can no longer be reasonable since the filing of this action in which it was specifically detailed how their conduct violates that statute.

So having addressed Respondents' arguments about the applicability of the statutes, I briefly wanted to return to the factual record. Dr. Almgren's testimony involved, you know, a significant number of technical terms and concepts. However, distilled to its essence, there's a number of rather simple facts at issue here and we believe that the record that was just introduced demonstrates that they are unrebutted and clear. And that is that TDCJ receives pentobarbital in two different sized vials: 50 milliliters, and 100 milliliters, and

1 12:17PM 12:17PM 2

12:17PM

4 12:17PM

3

5 12:17PM 12:17PM 6

12:17PM 7

8 12:18PM

12:18PM 9

10 12:18PM

11 12:18PM

12 12:18PM

13 12:18PM

14 12:18PM

15 12:18PM

16 12:18PM

17 12:18PM

18 12:18PM

19 12:18PM

20 12:18PM

21 12:18PM

22 12:18PM

12:19PM 23

24 12:19PM

25 12:19PM

that TDCJ last received new 100 milliliter vials in April of 2019 and last received 50 milliliter vials in March of 2021.

Dr. Almgren explained that these are considered high risk sterile compounded preparations and that the USP sets forth careful and detailed expiration dates for these high risk preparations. And those are 24 hours at room temperature, three days in refrigeration and 45 days in a solid frozen state.

All vials in TDCJ's possession are expired. That record is undisputed, as per USP. The 100 milliliter vials expired in June of 2019. milliliter vials expired in May of 2021.

You also heard Dr. Almgren explain how Respondents claimed to extend the beyond-use dates beyond what is recognized as a scientifically valid deadline, and that is by on occasion sending out a vial for a potency test alone, then claiming to extend the expiration date of all the vials in their possession for up to 11 months at a time.

You also heard Dr. Almgren explain these actions violate USP and Respondents have violated USP upon initial compounding of pentobarbital in TDCJ's possession. There is no record that any vial was ever subjected to pH testing or to a visual inspection and

that when TDCJ performed sterility test they, in fact, performed the wrong test.

You also heard Dr. Almgren clearly explain that these vials as a matter of pharmaceutical science are expired and have been expired between 20 and 43 months.

You also heard Dr. Almgren explain that the methods that Respondents use to claim to extend the beyond-use dates are completely unscientific and invalid. But the only valid way to extend the expiration date of a drug is with a stability indicating test and that the potency test that TDCJ does is not a stability indicating test and will give a false picture of how potent the drugs are.

Rather TDCJ uses the potency test alone and claims to extend the beyond-use dates. Even if you could use the potency test alone, which you cannot, Dr. Almgren explained that the way that TDCJ is using these potency tests is further invalid under the USP. It is invalid to take a vial from one batch and then say, based on the test of that one vial, all of the vials in your possession are expired. That is not a scientific method or conclusion to reach.

Dr. Almgren offered the conclusion that these drugs are expired under USP and that the beyond-use

12:19PM 12:19PM 3 12:19PM 4 12:19PM 5 12:19PM 6 12:19PM 7 12:19PM 8 12:19PM 9 12:19PM 10 12:19PM 11 12:19PM 12 12:19PM 13 12:19PM 14 12:19PM 15 12:20PM 16 12:20PM 17 12:20PM 18 12:20PM 19 12:20PM 20 12:20PM 21 12:20PM 22 12:20PM 23 12:20PM 24 12:20PM 25 12:20PM

12:20PM **1**12:20PM **2**

12:20PM **3**

12:20PM 4

12:20PM 5

12:21PM 6

12:21PM **7**

12:21PM 8

12:21PM 9

12:21PM 10

12:21PM **11**

12:21PM **12**

12:21PM 13

12:21PM **14**

12:21PM 15

12:21PM **16**

12:21PM **17**

12:21PM 18

12:21PM 19

12:21PM 20

12:21PM **21**

12:22PM **22**

12:22PM 23

12:22PM **24**

12:22PM **25**

date must be disregarded that Respondents have claimed to admit.

In their response to the emergency motion, Respondents seem to disregard the clear conclusions under USP and instead have offered their own definition of when a drug is considered expired. They claim that for purposes of an execution a drug is unexpired if it retains sufficient potency -- and I want to quote the language -- so that it is "Quickly effective so that no pain or suffering will be experienced."

Even if that was a definition, that was acceptable under USP or the Texas Pharmacy Act, the evidence demonstrates that they are not meeting their own standard of expiration. Dr. Almgren was clearly explaining that even if a drug returns a test result on a potency test in a sufficient range, it nonetheless poses risk of harm and suffering upon administration.

So therefore, even accepting Respondents' own definition of an expired drug, these drugs are expired. So in this way the record demonstrates that Respondents are in violation of multiple state statutes when they procure, compound, maintain and then administer the pentobarbital in TDCJ's possession.

Each of the failures that I just outlined to comply with USP is a violation of the Pharmacy Act.

12:22PM 12:22PM 2

1

3 12:22PM

4 12:22PM

5 12:22PM

12:22PM 6

7 12:22PM

8 12:22PM

9 12:22PM

10 12:22PM

11 12:22PM

12 12:23PM

13 12:23PM

14 12:23PM

15 12:23PM

16 12:23PM

17 12:23PM

18 12:23PM

19 12:23PM

20 12:23PM

21 12:23PM

22 12:23PM

12:23PM 23

24 12:23PM

25 12:23PM

First the Pharmacy Act requires compliance with USP on initial compounding; Respondents are not doing that. USP says that expired drugs may not be administered; Respondents are not doing that. And USP says that you may not prepare amounts of a compounded drug in excess of what you reasonably expect to administer prior to an expiration date. In other words, USP and the Pharmacy Act prohibits stockpiling drugs. That is what Respondents are doing. That's a further violation of USP.

And the Pharmacy Act and the Texas Controlled Substances Act, the Texas Food, Drug and Cosmetics Act, the Texas Penal Code all require a prescription to possess, distribute or administer pentobarbital. No prescriptions have been produced to us in response to multiple Public Information Act requests; therefore, Respondents lack legal authority under these statutes to administer pentobarbital to Petitioners.

So I've just outlined the causes of action stated in the complaint, how the evidence introduced today demonstrates a probable right to relief under each of these claims. And I would like to briefly touch on the evidence that demonstrates that, absent this Court's intervention, Petitioners will suffer probable imminent irreparable injury.

1 12:23PM 2 12:23PM 3 12:23PM 4 12:24PM 5 12:24PM 12:24PM 6 7 12:24PM 8 12:24PM 9 12:24PM 10 12:24PM 11 12:24PM 12 12:24PM 13 12:24PM 14 12:24PM 15 12:24PM 16 12:24PM 17 12:24PM 18 12:24PM 19 12:24PM 20 12:25PM 21 12:25PM 22 12:25PM 12:25PM 23 24 12:25PM 25 12:25PM

As Dr. Almgren explained, as a drug degrades it can turn into a completely different compound that will act upon the body in a way that pentobarbital is not intended to act, and that as a drug ages precipitants form and that those precipitants can cause pain at the injection site and can clog IV lines. It also appears and is worth noting again that TDCJ has not subjected any of the vials in its possession to --

THE COURT: I'm sorry. To what? What did you say? I missed the last part.

MS. NELSON-MAJOR: I was saying it's worth noting in this context again that Respondents have not subjected, based on the records before us, any of the vials to pH testing. And that's significant because as a drug ages pH can change, and that can lead to a whole host of issues, including pain upon injection and further causing degradants and particulates to form.

Dr. Almgren also discussed how Respondents' handling of the drugs exposes the vials to contaminants which can cause vomiting, nausea, pain, renal failure and Dr. Almgren also explained that these risks increase the further past the expiration date you are.

And because Petitioners can't be adequately redressed for the risk of these harms absent this Court's intervention -- because if these harms occurred during

12:25PM 1 their ex

3

12:25PM **4**

12:25PM

12:25PM **5**

12:25PM 6

12:25PM **7**

12:25PM **8**

12:25PM 9

12:25PM 10

12:26PM 11

12:26PM 12

12:26PM 13

12:26PM **14**

12:26PM 15

12:26PM 16

12:26PM **17**

12:26PM 18

12:26PM 19

12:26PM 20

12:26PM **21**

12:26PM **22**

12:26PM 23

12:26PM 24

12:26PM **25**

their execution, Petitioners will obviously be dead and no longer able to pursue a form in which to have these important allegations heard.

Therefore, this Court should grant the request for a temporary injunction and issue an order prohibiting Respondents from procuring, possessing, distributing or administering pentobarbital to Petitioners in violation of the Texas Pharmacy Act, the Texas Controlled Substances Act, the Texas Penal Code, and the Texas Food, Drug and Cosmetics Act. Therefore, the record adequately demonstrates the issuance of the temporary injunction is justified and necessary in this case. Thank you, Your Honor.

THE COURT: Thank you, Ms. Nelson-Major. Ms. O'Leary.

MS. O'LEARY: Yes, Your Honor. I'll just respondent to a couple of those points, if I may.

First, even if <u>Blaze vs. Rees</u> didn't apply -- which is the Supreme Court case that sets the standard for challenges to the method of execution, which this case can certainly be categorized as that -- even if this didn't apply, an injunction requires they show a probable irreparable imminent injury. And an injury, when it comes to lethal injection, is that it's going to cause more pain than it normally would. And by "normally

12:26PM	1	would" I mean it doesn't feel
12:26PM	2	THE COURT: Isn't that violative of the
12:26PM	3	penal statutes that govern how executions are supposed to
12:27PM	4	be carried out?
12:27PM	5	MS. O'LEARY: I'm sorry, Your Honor. The
12:27PM	6	Code of Criminal Procedure is the lethal injection
12:27PM	7	statute.
12:27PM	8	THE COURT: Okay. All right.
12:27PM	9	MS. O'LEARY: And the provision of the
12:27PM	10	penal code that Petitioners allege is being violated is
12:27PM	11	bringing a controlled substance into a correctional
12:27PM	12	facility.
12:27PM	13	THE COURT: All right. Go ahead.
12:27PM	14	MS. O'LEARY: The Petitioners cannot show
12:27PM	15	an imminent injury because they cannot show that any pain
12:27PM	16	or suffering is going to be experienced beyond just what
12:27PM	17	it feels like to have blood drawn when the IV's are
12:27PM	18	placed.
12:27PM	19	THE COURT: How would anyone other than
12:27PM	20	the expert testimony I've heard today from a
12:27PM	21	pharmacologist, how could that ever be established?
12:27PM	22	MS. O'LEARY: Well, Your Honor, the media
12:27PM	23	and witnesses are present at every single execution and
12:28PM	24	they describe what they see in every execution. The
12:28PM	25	Petitioners haven't presented evidence of a single

1 12:28PM 2 12:28PM 3 12:28PM 4 12:28PM 5 12:28PM 12:28PM 6 7 12:28PM 8 12:28PM 9 12:28PM 10 12:28PM 11 12:28PM 12 12:28PM 12:28PM 13 14 12:29PM 15 12:29PM 16 12:29PM 17 12:29PM 18 12:29PM 19 12:29PM 20 12:29PM 21 12:29PM 22 12:29PM 12:29PM 23

24

25

12:29PM

12:29PM

execution where any abnormal pain or suffering has been observed. The sounds, movements, eye movements, all of those details are described for each execution. And since I can't prove a negative, the Petitioners have the burden here. They haven't presented that a single execution in Texas history, and not since 2013 when single does pentobarbital began its use, has this terrible problem that they are describing ever occurred.

Additionally, Your Honor, the Pharmacy Act, the categories are listed in the statute, it's laid out in our briefing; it applies to certain categories of actors. It applies to a provider prescribing medications to their patient, it provides a pharmacy compounding solutions for another pharmacy. Categories like that; certainly no category that TDCJ or its actors fall into. The controlled substances --

THE COURT: What about -- let me ask about the Pharmacy Act. What about the second -- Ms. Nelson-Major told me was the second legislative, the purpose of the Pharmacy Act was to regulate pharmacies and pharmaceuticals consistent with the purposes of the act. Because they are used for execution purposes, is it your position that the Respondents are taken out of requirements to comply with the Pharmacy Act? Is there an exception in the Pharmacy Act that says for purposes

of execution we don't have to comply with those provisions?

MS. O'LEARY: There is not an explicit exception that says "executions," Your Honor, but certainly there are -- that is the general stated purpose. It says, "To regulate the practice of pharmacy and licensing pharmaceuticals who engage in the practice of treating illness, injury or disease." And so the -- then it lists categories of actors that it applies to. In case the stated overall purpose is too broad or not specific enough, then it goes on to list who it applies to. And it certainly doesn't apply to TDCJ, it doesn't apply to lethal doses of pentobarbital, things that are not used for therapeutic purposes.

THE COURT: Let me ask you another question. Why does TDCJ test the drugs in its possession periodically? If they are not worried about the efficacy, the potency, the stability of those drugs, why are they even tested?

MS. O'LEARY: We certainly can't say that they are not worried about the potency or efficacy, Your Honor. They are not doing that in order to comply with the Texas Pharmacy Act; they are doing that to comply with the 8th Amendment, to be sure they have effective, potent drugs when it's time to use them, because

12:29PM 12:29PM 3 12:29PM 4 12:29PM 5 12:29PM 12:30PM 6 12:30PM 7 8 12:30PM 9 12:30PM 10 12:30PM 12:30PM 11 12 12:30PM 13 12:30PM 14 12:30PM 15 12:30PM 16 12:30PM 17 12:30PM 18 12:30PM 19 12:30PM 20 12:30PM 21 12:30PM 22 12:31PM 12:31PM 23 24 12:31PM 25 12:31PM

1 12:31PM 12:31PM 2 3 12:31PM 4

12:31PM

5 12:31PM 12:31PM 6 7 12:31PM 8 12:31PM

10 12:31PM 11 12:31PM

9

12:31PM

12 12:31PM 13 12:31PM

14 12:31PM

15 12:31PM

16 12:32PM

17 12:32PM

18 12:32PM

19 12:32PM

20 12:32PM

22 12:32PM

12:32PM

21

12:32PM 23

24 12:32PM

25 12:32PM

certainly they are interested in carrying out executions in the most humane way possible. And they are regulated by the 8th Amendment; they are not regulated by pharmaceutical standards.

THE COURT: But isn't the pharmacist, whoever compounded the drugs, aren't they regulated by those standards? Is it your position that once they are put out and given to TDCJ that, therefore, none of the pharmaceutical regulations apply and, therefore, the Respondents can just take some drugs, they are out of date, and use them however they see fit?

MS. O'LEARY: No, Your Honor. confidential pharmacy and whoever is conducting the lab testing for TDCJ, they simply don't fall into these categories under the Pharmacy Act. They are not dispensing a drug for a Class A pharmacy, to the practitioner for the office's use. They just don't fall into those categories, because the Pharmacy Act was not written to cover this kind of situation, and so the categories it describes don't capture it.

Another point, Your Honor, that I think is important to discuss is that ultra vires claims cannot lie if there is conflicting statutory authority. An ultra vires claim is for an official who is acting without authority.

1 12:32PM 12:32PM 2 3 12:32PM 4 12:32PM 5 12:32PM 12:32PM 6 7 12:32PM 8 12:32PM 12:33PM 9 10 12:33PM 11 12:33PM 12 12:33PM 13 12:33PM 14 12:33PM 15 12:33PM 16 12:33PM 17 12:33PM

18

12:33PM

Now, if you look at the Code of Criminal Procedure, the statute directs TDCJ to carry out executions by lethal injection. Now, implicit in that mandate is that a lethal injection is going to be conducted using a controlled substance. That's the only humane way to do it; that's the only type of substance that could be effective for lethal injection. that mandate implicitly requires TDCJ to administer a controlled substance. It also implicitly requires that substance to be administered without a prescription from a medical provider because a medical provider cannot ethically prescribe a medication to kill somebody. Hippocratic oath.

THE COURT: Mr. Kursman, hold on. You will have a chance to respond.

Go ahead, Ms. O'Leary.

MS. O'LEARY: They have the hippocratic oath. Nursing and non-doctor medical providers have similar ethical responsibilities. They cannot write a prescription that is meant as a lethal does to kill somebody. And so when we have a statute from the a controlled substance, that context matters. authority that has to be done, and implicitly that means certain things. And so the medical provider can't be

19 12:33PM 20 12:33PM 21 12:33PM legislature directing TDCJ to administer a lethal does of 22 12:33PM 12:33PM 23 24 12:33PM 25 12:33PM

12:33PM **1**

12:33PM 2

12:34PM **3**

12:34PM **4**

12:34PM **5**

12:34PM 6

12:34PM **7**

12:34PM 8

12:34PM 9

12:34PM 10

12:34PM **11**

12:34PM **12**

12:34PM 13

12:34PM **14**

12:34PM 15

12:34PM **16**

12:34PM 17

12:34PM 18

12:34PM 19

12:35PM **20**

12:35PM **21**

12:35PM **22**

12:35PM 23

12:35PM **24**

12:35PM **25**

directly involved in the prescription.

So each of these acts that the Petitioners have listed, they are citing to portions that require a prescription from a provider. And while clever, as the Court of Criminal Appeals noted, it conflicts with the statute that directs TDCJ to carry out lethal injection. And so whether there's conflicting statute, it cannot be said that these officials are acting without authority.

And then I'll address Dr. Almgren quickly. She acknowledged a scientific study that she had read just last night. That study found that compounded pentobarbital has a shelf life of up to six years, that it degrades at half a percent per year and she disagrees was the methodology, and that's fine. It's another study by another pharmaceutical scientist. Reasonable minds can differ, even when it comes to scientific methodology. So that is the only point that I want to make with Dr. Almgren, is that her methodology is different and because the Pharmacy Act doesn't apply to TDCJ, the methodology that she prefers does not have to be used here.

Additionally, the USP, United States

Pharmacologica [sic], only portions of that are codified in the administrative code, so the exhibits we saw citing

to the USP, we don't know if those are actually codified. 1 The USP is not a statute and certainly someone cannot act 2 ultra vires by violating standards, United States 3 standards for pharmacology. 4 12:35PM

> The penal code -- just very quickly. Petitioners in their argument said that we cited no authority at all to say that we're exempt from the Penal But we cited 9.21(a) of the Penal Code that specifically says that a state official carrying out a legal court order for a legal process can do what they need to, even if it violates the Penal Code. So that exception is quite clear.

And again, even if it wasn't, when you have a conflicting statute like the one that directs the director of TDCJ correctional institutions to carry out a lethal injection, implicitly he has to take certain action in order to comply with that statute. And that means administering pentobarbital without a prescription and in a correctional facility. And unless the Court has any other questions, that concludes my argument.

Thank you. THE COURT: I'll let the Petitioners close the argument. I don't know if it's Mr. Kursman or Ms. Nelson-Major.

What you heard from Ms. O'Leary was just a

Sure, Your Honor.

12:35PM 12:35PM 12:35PM

5 12:35PM 12:35PM 6

12:35PM 7 8 12:35PM

9 12:35PM

10 12:36PM

11 12:36PM

12 12:36PM

12:36PM

14 12:36PM

13

15 12:36PM

16 12:36PM

17 12:36PM

18 12:36PM

19 12:36PM

20 12:36PM

21 12:36PM

22 12:36PM

12:36PM 23

24 12:36PM

25 12:36PM

MR. KURSMAN:

12:36PM **1**

12:37PM **2**

12:37PM **3**

12:37PM 4

12:37PM **5**

12:37PM 6

12:37PM **7**

12:37PM **8**

12:37PM 9

12:37PM 10

12:37PM **11**

12:37PM 12

12:37PM 13

12:37PM **14**

12:37PM 15

12:37PM **16**

12:37PM **17**

12:37PM 18

12:38PM 19

12:38PM **20**

12:38PM 21

12:38PM **22**

12:38PM **23**

12:38PM **24**

12:38PM **25**

bunch of purported facts that were never introduced into evidence. One of those purported facts were that doctors can't write a prescription. Well, not only was that not produced in evidence; it simply not true. Other states, including the State of Tennessee, obtains a prescription for every execution. So we have no way to challenge these facts, these purported facts, that Ms. O'Leary has just stated because she hasn't entered any of these in evidence.

Every fact that was entered today in evidence was from the Petitioners and every single one of those facts went virtually unrebutted. We have proven by clear evidence that the Respondents are violating all of the statutes that we had named; therefore, we would request that you grant the requested preliminary injunction. Thank you, Your Honor.

THE COURT: Thank you. All of the decisions I make on the Bench are important. I have to say this one weighs on me particularly heavily, given the exigent nature of the requested relief, which requires me to make a decision in the next few hours, as well as --well, just as well as what's at issue here. I want to go back and look at a couple of these statutes. I'll get you-all a ruling within the next -- no later than two hours. I understand what the deadlines are and I

understand the importance of the ruling I'm about to make.

I also am very clear and cognizant of the Court of Criminal Appeal's opinion and I would -- do not purport in any way to attempt to stay or set aside the sentences that have been leveled against the Petitioners and the Intervenors or to attempt to stay their execution dates.

I think the State -- I haven't heard any evidence about whether or not the State can get anymore unexpired pentobarbital. The State is certainly entitled to carry out the executions that have been ordered with unexpired drugs. What I'm going to decide is whether or not the State is permitted to use expired drugs, and I'll get you an order and a decision just within the next couple of hours. It will be e-mailed to all counsel.

Thank you-all very much. You may be excused.

MR. WILSON: Your Honor, if I may. Daniel Wilson. Throughout the hearing we've been preparing a potential proposed order that tracks a lot of what I've heard. Would the Court find that helpful?

THE COURT: Yes. Both sides are invited to send me proposed orders. Please send them to my submission e-mail address.

12:38PM 12:38PM 3 12:38PM 4 12:38PM 5 12:38PM 12:38PM 6 7 12:38PM 8 12:39PM 12:39PM 9 10 12:39PM 11 12:39PM 12 12:39PM 13 12:39PM 14 12:39PM 15 12:39PM 16 12:39PM 17 12:39PM 18 12:39PM 19 12:39PM 20 12:39PM 21 12:39PM 22 12:39PM 12:39PM 23 24 12:39PM 25 12:39PM

1	(Proceedings concluded.)
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

REPORTER'S CERTIFICATE 1 2 STATE OF TEXAS 3 4 COUNTY OF TRAVIS I, Leah Hayes, Official Court Reporter in and for 5 the 419th District Court of Travis County, State of 6 7 Texas, do hereby certify that the above and foregoing contains a true and correct transcription of all portions of evidence and other proceedings requested in writing by counsel for the parties to be included in this volume of 10 the Reporter's Record, in the above-styled and numbered 11 12 cause, all of which occurred REMOTELY VIA VIDE CONFERENCE and were reported by me. 13 I further certify that this Reporter's Record of the 14 proceedings truly and correctly reflects the exhibits, if 15 any, offered in evidence by the respective parties. 16 17 WITNESS MY OFFICIAL HAND this the 15th day of 18 January, 2023. 19 /s/ Leah Hayes 20 Leah Hayes, Texas CSR No. 3973 Expiration Date: 07/31/2023 21 Texas Certified Realtime Reporter Official Court Reporter 22 419th District Court Travis County, Texas Austin, Texas 78701 23 (512) 854-9329 24 25